CleftGeneDB-Search

Gene: FGF2

Basic information

Tag	Content
Uniprot ID	P09038; A4LBB8; O00527; P78443; Q16443; Q5PY50; Q7KZ11; Q7KZ72; Q9UC54; Q9UCS5; Q9UCS6;
Entrez ID	2247
Genbank protein ID	CAA28029.1; AAB21432.2; AAD13853.1; CAA28028.1; CAA73868.1; AAA52448.1; EAX05222.1; AAA52534.1; AAA52532.1; AAA52533.1; CAA28027.1; BAG70135.1; BAG70264.1; AAV70487.1; AAA52531.1; ABO43041.1;
Genbank nucleotide ID	NM_002006.4
Ensembl protein ID	ENSP00000494222; ENSP00000477134; ENSP00000478620;
Ensembl nucleotide ID	ENSG00000138685
Gene name	Fibroblast growth factor 2
Gene symbol	FGF2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	14755461
Functional description	Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:8663044). Also acts as an integrin ligand which is required for FGF2 signaling (PubMed:28302677). Binds to integrin ITGAV:ITGB3 (PubMed:28302677). Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration (PubMed:8663044, PubMed:28302677). Functions as a potent mitogen in vitro (PubMed:1721615, PubMed:3964259, PubMed:3732516). Can induce angiogenesis (PubMed:23469107, PubMed:28302677). Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation (PubMed:29501879).
Sequence	MVGVGGGDVE DVTPRPGGCQ ISGRGARGCN GIPGAAAWEA ALPRRRPRRH PSVNPRSRAA 60 GSPRTRGRRT EERPSGSRLG DRGRGRALPG GRLGGRGRGR APERVGGRGR GRGTAAPRAA 120 PAARGSRPGP AGTMAAGSIT TLPALPEDGG SGAFPPGHFK DPKRLYCKNG GFFLRIHPDG 180 RVDGVREKSD PHIKLQLQAE ERGVVSIKGV CANRYLAMKE DGRLLASKCV TDECFFFERL 240 ESNNYNTYRS RKYTSWYVAL KRTGQYKLGS KTGPGQKAIL FLPMSAKS 288

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1BAS
1BFB
1BFC
1BFF
1BFG
1BLA
1BLD
1CVS
1EV2
1FGA
1FQ9
1II4
1IIL
2BFH
2FGF
2M49
4FGF
4OEE
4OEF
4OEG
5X1O
1BFG
1BLA
2FGF

Protein disorder information

Orthologous information

There is no orthologous record for this gene !

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
FGF2	rs11737764C>T	Genotyping	21462296
FGF2	rs308434C>T	Genotyping	21462296
FGF2	rs308441C>T	Genotyping	21462296

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1277657893	p.Val2Gly	missense variant	-	NC_000004.12:g.122826780T>G	TOPMed
rs755065230	p.Gly3Cys	missense variant	-	NC_000004.12:g.122826782G>T	ExAC,TOPMed,gnomAD
rs75664870	p.Gly5Arg	missense variant	-	NC_000004.12:g.122826788G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs75664870	p.Gly5Trp	missense variant	-	NC_000004.12:g.122826788G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs201837669	p.Gly5Glu	missense variant	-	NC_000004.12:g.122826789G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs201172719	p.Gly6Asp	missense variant	-	NC_000004.12:g.122826792G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs776164719	p.Gly6ValPheSerTerUnk	frameshift	-	NC_000004.12:g.122826787G>-	NCI-TCGA,NCI-TCGA Cosmic
rs1365155611	p.Asp8Asn	missense variant	-	NC_000004.12:g.122826797G>A	gnomAD
rs1172502103	p.Asp8Glu	missense variant	-	NC_000004.12:g.122826799T>A	TOPMed
rs1468330442	p.Val9Ala	missense variant	-	NC_000004.12:g.122826801T>C	gnomAD
rs1422731313	p.Asp11Gly	missense variant	-	NC_000004.12:g.122826807A>G	TOPMed
rs1406176309	p.Asp11Asn	missense variant	-	NC_000004.12:g.122826806G>A	gnomAD
rs1013771225	p.Val12Leu	missense variant	-	NC_000004.12:g.122826809G>C	TOPMed
rs937369236	p.Val12Gly	missense variant	-	NC_000004.12:g.122826810T>G	gnomAD
rs1486411520	p.Thr13Ser	missense variant	-	NC_000004.12:g.122826812A>T	TOPMed
rs775088697	p.Thr13Met	missense variant	-	NC_000004.12:g.122826813C>T	ExAC,TOPMed,gnomAD
rs1320375372	p.Pro14Leu	missense variant	-	NC_000004.12:g.122826816C>T	gnomAD
rs867675421	p.Arg15Gln	missense variant	-	NC_000004.12:g.122826819G>A	TOPMed
rs1345803406	p.Arg15Trp	missense variant	-	NC_000004.12:g.122826818C>T	gnomAD
rs763538114	p.Gly17Asp	missense variant	-	NC_000004.12:g.122826825G>A	ExAC,gnomAD
rs574867967	p.Gly17Ser	missense variant	-	NC_000004.12:g.122826824G>A	1000Genomes,ExAC,gnomAD
rs1337751706	p.Gly18Arg	missense variant	-	NC_000004.12:g.122826827G>A	gnomAD
rs1253573035	p.Gln20His	missense variant	-	NC_000004.12:g.122826835G>C	TOPMed
rs776193603	p.Ser22Arg	missense variant	-	NC_000004.12:g.122826841C>A	ExAC,gnomAD
rs761725675	p.Gly23Ter	stop gained	-	NC_000004.12:g.122826842G>T	ExAC,TOPMed,gnomAD
rs761725675	p.Gly23Arg	missense variant	-	NC_000004.12:g.122826842G>C	ExAC,TOPMed,gnomAD
rs761725675	p.Gly23Arg	missense variant	-	NC_000004.12:g.122826842G>A	ExAC,TOPMed,gnomAD
rs1046220867	p.Arg24His	missense variant	-	NC_000004.12:g.122826846G>A	TOPMed,gnomAD
rs1046220867	p.Arg24Pro	missense variant	-	NC_000004.12:g.122826846G>C	TOPMed,gnomAD
rs1353746482	p.Ala26Asp	missense variant	-	NC_000004.12:g.122826852C>A	TOPMed
rs1235542932	p.Ala26Thr	missense variant	-	NC_000004.12:g.122826851G>A	TOPMed
rs750232897	p.Arg27Ser	missense variant	-	NC_000004.12:g.122826854C>A	ExAC,gnomAD
rs1482911855	p.Arg27Leu	missense variant	-	NC_000004.12:g.122826855G>T	gnomAD
rs1196141411	p.Gly28Asp	missense variant	-	NC_000004.12:g.122826858G>A	gnomAD
rs1252484277	p.Cys29Phe	missense variant	-	NC_000004.12:g.122826861G>T	gnomAD
rs902408256	p.Cys29Trp	missense variant	-	NC_000004.12:g.122826862C>G	TOPMed,gnomAD
rs758218301	p.Asn30Ser	missense variant	-	NC_000004.12:g.122826864A>G	ExAC,TOPMed,gnomAD
rs1347292841	p.Asn30His	missense variant	-	NC_000004.12:g.122826863A>C	gnomAD
rs979153928	p.Asn30Lys	missense variant	-	NC_000004.12:g.122826865C>G	TOPMed
rs537528863	p.Pro33Leu	missense variant	-	NC_000004.12:g.122826873C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs537528863	p.Pro33Arg	missense variant	-	NC_000004.12:g.122826873C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1466037704	p.Ala35Thr	missense variant	-	NC_000004.12:g.122826878G>A	gnomAD
rs1165309821	p.Ala36Thr	missense variant	-	NC_000004.12:g.122826881G>A	TOPMed
rs1342473116	p.Trp38Ter	stop gained	-	NC_000004.12:g.122826889G>A	gnomAD
rs1389843429	p.Trp38Leu	missense variant	-	NC_000004.12:g.122826888G>T	gnomAD
rs925186805	p.Glu39Gly	missense variant	-	NC_000004.12:g.122826891A>G	TOPMed
rs369126645	p.Ala41Ser	missense variant	-	NC_000004.12:g.122826896G>T	ESP,ExAC,gnomAD
rs1225041132	p.Leu42Val	missense variant	-	NC_000004.12:g.122826899C>G	gnomAD
rs1225041132	p.Leu42Phe	missense variant	-	NC_000004.12:g.122826899C>T	gnomAD
rs756631593	p.Pro43Ser	missense variant	-	NC_000004.12:g.122826902C>T	ExAC,gnomAD
rs756631593	p.Pro43Thr	missense variant	-	NC_000004.12:g.122826902C>A	ExAC,gnomAD
rs1281514668	p.Pro43Leu	missense variant	-	NC_000004.12:g.122826903C>T	TOPMed,gnomAD
rs778297907	p.Arg45Gln	missense variant	-	NC_000004.12:g.122826909G>A	ExAC,TOPMed,gnomAD
rs1311526628	p.Arg45Trp	missense variant	-	NC_000004.12:g.122826908C>T	gnomAD
rs778297907	p.Arg45Leu	missense variant	-	NC_000004.12:g.122826909G>T	ExAC,TOPMed,gnomAD
rs749687881	p.Arg46Cys	missense variant	-	NC_000004.12:g.122826911C>T	ExAC,TOPMed,gnomAD
rs771218306	p.Arg46His	missense variant	-	NC_000004.12:g.122826912G>A	ExAC,gnomAD
rs1203947549	p.Pro47Gln	missense variant	-	NC_000004.12:g.122826915C>A	gnomAD
rs1490755234	p.Arg48Trp	missense variant	-	NC_000004.12:g.122826917C>T	gnomAD
rs775137950	p.Arg48Gln	missense variant	-	NC_000004.12:g.122826918G>A	ExAC,gnomAD
rs1171762386	p.Pro51Ala	missense variant	-	NC_000004.12:g.122826926C>G	gnomAD
rs1428188294	p.Val53Met	missense variant	-	NC_000004.12:g.122826932G>A	gnomAD
rs776042904	p.Asn54Thr	missense variant	-	NC_000004.12:g.122826936A>C	ExAC,TOPMed,gnomAD
rs776042904	p.Asn54Ile	missense variant	-	NC_000004.12:g.122826936A>T	ExAC,TOPMed,gnomAD
rs765107715	p.Pro55Ala	missense variant	-	NC_000004.12:g.122826938C>G	ExAC,TOPMed,gnomAD
rs765107715	p.Pro55Ser	missense variant	-	NC_000004.12:g.122826938C>T	ExAC,TOPMed,gnomAD
rs773244197	p.Arg56Lys	missense variant	-	NC_000004.12:g.122826942G>A	ExAC,gnomAD
rs762842666	p.Arg58Gln	missense variant	-	NC_000004.12:g.122826948G>A	ExAC,TOPMed,gnomAD
rs912411112	p.Arg58Trp	missense variant	-	NC_000004.12:g.122826947C>T	TOPMed,gnomAD
rs1227367770	p.Ala59Thr	missense variant	-	NC_000004.12:g.122826950G>A	gnomAD
rs1361070589	p.Ala60Thr	missense variant	-	NC_000004.12:g.122826953G>A	gnomAD
rs1361070589	p.Ala60Pro	missense variant	-	NC_000004.12:g.122826953G>C	gnomAD
rs751383303	p.Ala60Asp	missense variant	-	NC_000004.12:g.122826954C>A	ExAC,gnomAD
rs751383303	p.Ala60Val	missense variant	-	NC_000004.12:g.122826954C>T	ExAC,gnomAD
rs1245576530	p.Gly61Ser	missense variant	-	NC_000004.12:g.122826956G>A	TOPMed,gnomAD
rs767760955	p.Ser62Leu	missense variant	-	NC_000004.12:g.122826960C>T	ExAC,TOPMed,gnomAD
rs767760955	p.Ser62Ter	stop gained	-	NC_000004.12:g.122826960C>A	ExAC,TOPMed,gnomAD
rs1388380648	p.Arg64His	missense variant	-	NC_000004.12:g.122826966G>A	TOPMed
rs931304683	p.Arg66Lys	missense variant	-	NC_000004.12:g.122826972G>A	TOPMed,gnomAD
rs1408983616	p.Gly67Cys	missense variant	-	NC_000004.12:g.122826974G>T	TOPMed,gnomAD
rs1408983616	p.Gly67Arg	missense variant	-	NC_000004.12:g.122826974G>C	TOPMed,gnomAD
rs1162972725	p.Arg68Gln	missense variant	-	NC_000004.12:g.122826978G>A	TOPMed,gnomAD
rs1048407271	p.Arg68Trp	missense variant	-	NC_000004.12:g.122826977C>T	TOPMed,gnomAD
rs1048407271	p.Arg68Gly	missense variant	-	NC_000004.12:g.122826977C>G	TOPMed,gnomAD
rs1367392769	p.Arg73Gln	missense variant	-	NC_000004.12:g.122826993G>A	TOPMed,gnomAD
rs1367392769	p.Arg73Leu	missense variant	-	NC_000004.12:g.122826993G>T	TOPMed,gnomAD
rs1289699253	p.Pro74Gln	missense variant	-	NC_000004.12:g.122826996C>A	TOPMed
rs1362939306	p.Ser75Asn	missense variant	-	NC_000004.12:g.122826999G>A	TOPMed,gnomAD
rs1434289357	p.Gly76Cys	missense variant	-	NC_000004.12:g.122827001G>T	TOPMed,gnomAD
rs1239476340	p.Gly76Val	missense variant	-	NC_000004.12:g.122827002G>T	TOPMed
rs756183320	p.Ser77Ter	stop gained	-	NC_000004.12:g.122827005C>A	ExAC,gnomAD
rs1443097372	p.Asp81Gly	missense variant	-	NC_000004.12:g.122827017A>G	TOPMed
rs1243274699	p.Arg82Gly	missense variant	-	NC_000004.12:g.122827019C>G	TOPMed,gnomAD
rs1243274699	p.Arg82Cys	missense variant	-	NC_000004.12:g.122827019C>T	TOPMed,gnomAD
rs1329076000	p.Gly83Arg	missense variant	-	NC_000004.12:g.122827022G>A	TOPMed,gnomAD
rs1386626033	p.Arg84Ser	missense variant	-	NC_000004.12:g.122827025C>A	TOPMed
rs1156505302	p.Arg86Gly	missense variant	-	NC_000004.12:g.122827031C>G	TOPMed
rs895975445	p.Ala87Gly	missense variant	-	NC_000004.12:g.122827035C>G	TOPMed
rs1395225787	p.Pro89Leu	missense variant	-	NC_000004.12:g.122827041C>T	TOPMed
rs1013302459	p.Gly90Ser	missense variant	-	NC_000004.12:g.122827043G>A	TOPMed
rs1246652416	p.Gly91Arg	missense variant	-	NC_000004.12:g.122827046G>A	TOPMed
rs1194287356	p.Leu93Val	missense variant	-	NC_000004.12:g.122827052C>G	TOPMed
rs1449129559	p.Gly94Arg	missense variant	-	NC_000004.12:g.122827055G>C	TOPMed
rs1000514172	p.Gly95Ser	missense variant	-	NC_000004.12:g.122827058G>A	TOPMed
rs1032038394	p.Gly95Ala	missense variant	-	NC_000004.12:g.122827059G>C	TOPMed
rs1032038394	p.Gly95Asp	missense variant	-	NC_000004.12:g.122827059G>A	TOPMed
rs1295953545	p.Arg98Gly	missense variant	-	NC_000004.12:g.122827067C>G	TOPMed
rs1399088258	p.Arg98Gln	missense variant	-	NC_000004.12:g.122827068G>A	TOPMed
rs953912785	p.Ala101Val	missense variant	-	NC_000004.12:g.122827077C>T	TOPMed
rs1422014013	p.Gly106Arg	missense variant	-	NC_000004.12:g.122827091G>C	TOPMed
rs1259898478	p.Arg108Trp	missense variant	-	NC_000004.12:g.122827097C>T	TOPMed
rs1208057703	p.Gly109Arg	missense variant	-	NC_000004.12:g.122827100G>C	TOPMed
RCV000190152	p.Gly109Asp	missense variant	Long QT syndrome (LQTS)	NC_000004.12:g.122827101G>A	ClinVar
rs796052159	p.Gly109Asp	missense variant	-	NC_000004.12:g.122827101G>A	TOPMed,gnomAD
rs1277804349	p.Arg110Gly	missense variant	-	NC_000004.12:g.122827103C>G	TOPMed
rs1463879546	p.Arg112Trp	missense variant	-	NC_000004.12:g.122827109C>T	TOPMed,gnomAD
rs1341209202	p.Gly113Ala	missense variant	-	NC_000004.12:g.122827113G>C	TOPMed
rs1184392826	p.Thr114Lys	missense variant	-	NC_000004.12:g.122827116C>A	TOPMed,gnomAD
rs1355645472	p.Ala115Val	missense variant	-	NC_000004.12:g.122827119C>T	TOPMed
rs1294781446	p.Ala116Thr	missense variant	-	NC_000004.12:g.122827121G>A	TOPMed
rs778152142	p.Ala122Val	missense variant	-	NC_000004.12:g.122827140C>T	ExAC,gnomAD
rs1419959409	p.Ala123Val	missense variant	-	NC_000004.12:g.122827143C>T	gnomAD
rs754286080	p.Ala123Ser	missense variant	-	NC_000004.12:g.122827142G>T	ExAC,gnomAD
rs757749553	p.Arg124Pro	missense variant	-	NC_000004.12:g.122827146G>C	ExAC,gnomAD
rs1386563271	p.Gly125Glu	missense variant	-	NC_000004.12:g.122827149G>A	TOPMed,gnomAD
rs779319256	p.Ser126Tyr	missense variant	-	NC_000004.12:g.122827152C>A	ExAC,gnomAD
rs779319256	p.Ser126Cys	missense variant	-	NC_000004.12:g.122827152C>G	ExAC,gnomAD
rs1156960709	p.Arg127Gly	missense variant	-	NC_000004.12:g.122827154C>G	TOPMed,gnomAD
rs1408264768	p.Pro128Leu	missense variant	-	NC_000004.12:g.122827158C>T	gnomAD
rs746202230	p.Pro128Ser	missense variant	-	NC_000004.12:g.122827157C>T	ExAC,TOPMed,gnomAD
rs746202230	p.Pro128Ala	missense variant	-	NC_000004.12:g.122827157C>G	ExAC,TOPMed,gnomAD
rs1445514854	p.Pro130Arg	missense variant	-	NC_000004.12:g.122827164C>G	TOPMed,gnomAD
rs1225114075	p.Met134Thr	missense variant	-	NC_000004.12:g.122827176T>C	TOPMed,gnomAD
rs1225114075	p.Met134Arg	missense variant	-	NC_000004.12:g.122827176T>G	TOPMed,gnomAD
rs1327888635	p.Ile139Thr	missense variant	-	NC_000004.12:g.122827191T>C	gnomAD
rs780846625	p.Thr141Met	missense variant	-	NC_000004.12:g.122827197C>T	ExAC,gnomAD
rs769276509	p.Ala144Ser	missense variant	-	NC_000004.12:g.122827205G>T	ExAC,TOPMed,gnomAD
rs769276509	p.Ala144Thr	missense variant	-	NC_000004.12:g.122827205G>A	ExAC,TOPMed,gnomAD
rs763038264	p.Leu145Phe	missense variant	-	NC_000004.12:g.122827210G>T	ExAC,gnomAD
rs770984817	p.Pro146Ser	missense variant	-	NC_000004.12:g.122827211C>T	ExAC,gnomAD
rs774338502	p.Pro146Arg	missense variant	-	NC_000004.12:g.122827212C>G	ExAC,gnomAD
rs1412760315	p.Gly149Asp	missense variant	-	NC_000004.12:g.122827221G>A	gnomAD
rs752901052	p.Gly150Ser	missense variant	-	NC_000004.12:g.122827223G>A	ExAC,gnomAD
rs760683900	p.Ala153Ser	missense variant	-	NC_000004.12:g.122827232G>T	ExAC,gnomAD
rs931444914	p.Ala153Asp	missense variant	-	NC_000004.12:g.122827233C>A	TOPMed
rs931444914	p.Ala153Val	missense variant	-	NC_000004.12:g.122827233C>T	TOPMed
rs377033294	p.Phe154Ser	missense variant	-	NC_000004.12:g.122827236T>C	ESP,ExAC,gnomAD
rs753911225	p.Pro155Leu	missense variant	-	NC_000004.12:g.122827239C>T	ExAC,TOPMed,gnomAD
rs753911225	p.Pro155Gln	missense variant	-	NC_000004.12:g.122827239C>A	ExAC,TOPMed,gnomAD
rs984059240	p.Pro155Ser	missense variant	-	NC_000004.12:g.122827238C>T	TOPMed
rs750806900	p.Pro156Ser	missense variant	-	NC_000004.12:g.122827241C>T	ExAC,TOPMed,gnomAD
rs780712893	p.Gly157Asp	missense variant	-	NC_000004.12:g.122827245G>A	ExAC,gnomAD
NCI-TCGA novel	p.Gly157Ser	missense variant	-	NC_000004.12:g.122827244G>A	NCI-TCGA
rs1308480387	p.His158Leu	missense variant	-	NC_000004.12:g.122827248A>T	gnomAD
COSM460698	p.Phe159Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122827252C>G	NCI-TCGA Cosmic
rs1388483162	p.Phe159Leu	missense variant	-	NC_000004.12:g.122827250T>C	gnomAD
rs1207110793	p.Phe159Ser	missense variant	-	NC_000004.12:g.122827251T>C	gnomAD
rs1200222343	p.Asp161Glu	missense variant	-	NC_000004.12:g.122827258C>A	gnomAD
rs777489946	p.Pro162His	missense variant	-	NC_000004.12:g.122827260C>A	ExAC,gnomAD
rs769315412	p.Pro162Ser	missense variant	-	NC_000004.12:g.122827259C>T	ExAC,TOPMed,gnomAD
rs748774402	p.Lys163Thr	missense variant	-	NC_000004.12:g.122827263A>C	ExAC,gnomAD
rs1369545744	p.Cys167Ser	missense variant	-	NC_000004.12:g.122827274T>A	TOPMed,gnomAD
rs1304371444	p.Gly170Trp	missense variant	-	NC_000004.12:g.122827283G>T	gnomAD
rs1434889412	p.Gly171Val	missense variant	-	NC_000004.12:g.122827287G>T	gnomAD
NCI-TCGA novel	p.Gly171Asp	missense variant	-	NC_000004.12:g.122827287G>A	NCI-TCGA
rs1363329019	p.Phe172Leu	missense variant	-	NC_000004.12:g.122827291C>A	gnomAD
rs1231050324	p.Phe173Ile	missense variant	-	NC_000004.12:g.122827292T>A	gnomAD
COSM3008948	p.Arg175Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122827298C>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ile176Phe	missense variant	-	NC_000004.12:g.122827301A>T	NCI-TCGA
rs1273011160	p.His177Asp	missense variant	-	NC_000004.12:g.122827304C>G	gnomAD
rs1341634346	p.Pro178Thr	missense variant	-	NC_000004.12:g.122827307C>A	gnomAD
COSM4613617	p.Asp179ThrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000004.12:g.122827306C>-	NCI-TCGA Cosmic
rs1316554552	p.Asp179Asn	missense variant	-	NC_000004.12:g.122827310G>A	gnomAD
rs771842609	p.Gly180Arg	missense variant	-	NC_000004.12:g.122827313G>C	ExAC,gnomAD
rs1236255682	p.Arg181Gly	missense variant	-	NC_000004.12:g.122827316C>G	TOPMed
rs764272274	p.Val182Asp	missense variant	-	NC_000004.12:g.122827320T>A	ExAC,gnomAD
rs761028222	p.Val182Leu	missense variant	-	NC_000004.12:g.122827319G>C	ExAC
rs761829108	p.Gly184Arg	missense variant	-	NC_000004.12:g.122827325G>A	ExAC,gnomAD
rs1389325875	p.Val185Ala	missense variant	-	NC_000004.12:g.122827329T>C	gnomAD
rs765761551	p.Val185Ile	missense variant	-	NC_000004.12:g.122827328G>A	ExAC,gnomAD
rs1424847946	p.Arg186Trp	missense variant	-	NC_000004.12:g.122827331C>T	gnomAD
rs1404216863	p.Ile193Val	missense variant	-	NC_000004.12:g.122827352A>G	gnomAD
rs148587537	p.Lys194Asn	missense variant	-	NC_000004.12:g.122876325G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1461756902	p.Lys194Ter	stop gained	-	NC_000004.12:g.122876323A>T	gnomAD
rs745342993	p.Glu200Gly	missense variant	-	NC_000004.12:g.122876342A>G	ExAC,gnomAD
rs1307758440	p.Glu201Ala	missense variant	-	NC_000004.12:g.122876345A>C	TOPMed
NCI-TCGA novel	p.Gly203Glu	missense variant	-	NC_000004.12:g.122876351G>A	NCI-TCGA
rs1182102110	p.Val204Ile	missense variant	-	NC_000004.12:g.122876353G>A	gnomAD
rs1471308253	p.Ser206Phe	missense variant	-	NC_000004.12:g.122876360C>T	gnomAD
NCI-TCGA novel	p.Ser206Pro	missense variant	-	NC_000004.12:g.122876359T>C	NCI-TCGA
rs776849106	p.Val210Ala	missense variant	-	NC_000004.12:g.122876372T>C	ExAC,gnomAD
rs113754132	p.Val210Leu	missense variant	-	NC_000004.12:g.122876371G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs557906415	p.Asn213Lys	missense variant	-	NC_000004.12:g.122876382C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1400532612	p.Asn213Asp	missense variant	-	NC_000004.12:g.122876380A>G	gnomAD
rs769999277	p.Arg214Cys	missense variant	-	NC_000004.12:g.122876383C>T	ExAC,TOPMed,gnomAD
rs1352612742	p.Arg214His	missense variant	-	NC_000004.12:g.122876384G>A	gnomAD
rs769999277	p.Arg214Gly	missense variant	-	NC_000004.12:g.122876383C>G	ExAC,TOPMed,gnomAD
rs1352612742	p.Arg214Pro	missense variant	-	NC_000004.12:g.122876384G>C	gnomAD
NCI-TCGA novel	p.Arg214Leu	missense variant	-	NC_000004.12:g.122876384G>T	NCI-TCGA
COSM732738	p.Tyr215Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000004.12:g.122876388C>A	NCI-TCGA Cosmic
rs762917513	p.Leu216Pro	missense variant	-	NC_000004.12:g.122876390T>C	ExAC,gnomAD
COSM732737	p.Met218Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122876397G>C	NCI-TCGA Cosmic
rs771501454	p.Met218Val	missense variant	-	NC_000004.12:g.122876395A>G	ExAC,gnomAD
rs771501454	p.Met218Leu	missense variant	-	NC_000004.12:g.122876395A>C	ExAC,gnomAD
NCI-TCGA novel	p.Asp221Tyr	missense variant	-	NC_000004.12:g.122876404G>T	NCI-TCGA
rs768053240	p.Arg223Thr	missense variant	-	NC_000004.12:g.122876411G>C	ExAC,gnomAD
rs768053240	p.Arg223Lys	missense variant	-	NC_000004.12:g.122876411G>A	ExAC,gnomAD
rs753112115	p.Leu225Val	missense variant	-	NC_000004.12:g.122876416C>G	ExAC,gnomAD
rs577765433	p.Ala226Thr	missense variant	-	NC_000004.12:g.122876419G>A	1000Genomes,ExAC,gnomAD
COSM5400415	p.Ala226Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122876420C>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Cys229Ter	stop gained	-	NC_000004.12:g.122892216T>A	NCI-TCGA
rs151141410	p.Thr231Met	missense variant	-	NC_000004.12:g.122892221C>T	ESP,ExAC,TOPMed,gnomAD
COSM1426728	p.Arg239Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000004.12:g.122892244C>T	NCI-TCGA Cosmic
rs1189001118	p.Arg239Gln	missense variant	-	NC_000004.12:g.122892245G>A	TOPMed,gnomAD
rs774476980	p.Ser242Phe	missense variant	-	NC_000004.12:g.122892254C>T	ExAC,gnomAD
rs774476980	p.Ser242Tyr	missense variant	-	NC_000004.12:g.122892254C>A	ExAC,gnomAD
rs772679777	p.Asn244Lys	missense variant	-	NC_000004.12:g.122892261C>A	ExAC,TOPMed
rs776049778	p.Tyr245Cys	missense variant	-	NC_000004.12:g.122892263A>G	ExAC,gnomAD
rs1168227898	p.Asn246Asp	missense variant	-	NC_000004.12:g.122892265A>G	gnomAD
NCI-TCGA novel	p.Asn246Tyr	missense variant	-	NC_000004.12:g.122892265A>T	NCI-TCGA
COSM6166072	p.Tyr248Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000004.12:g.122892273C>A	NCI-TCGA Cosmic
rs762535977	p.Arg249Gln	missense variant	-	NC_000004.12:g.122892275G>A	ExAC,TOPMed,gnomAD
rs749974017	p.Arg249Trp	missense variant	-	NC_000004.12:g.122892274C>T	ExAC,TOPMed,gnomAD
rs145325930	p.Lys252Asn	missense variant	-	NC_000004.12:g.122892285A>T	ESP,ExAC,TOPMed,gnomAD
rs1299477002	p.Thr254Asn	missense variant	-	NC_000004.12:g.122892290C>A	gnomAD
COSM1426729	p.Tyr257Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122892299A>T	NCI-TCGA Cosmic
rs751060740	p.Tyr257Cys	missense variant	-	NC_000004.12:g.122892299A>G	ExAC,TOPMed,gnomAD
rs1461924751	p.Val258Ala	missense variant	-	NC_000004.12:g.122892302T>C	TOPMed,gnomAD
NCI-TCGA novel	p.Val258TrpPheSerTerUnk	frameshift	-	NC_000004.12:g.122892301G>-	NCI-TCGA
rs754948013	p.Lys261Gln	missense variant	-	NC_000004.12:g.122892310A>C	ExAC,gnomAD
rs781084194	p.Arg262Ter	stop gained	-	NC_000004.12:g.122892313C>T	ExAC,gnomAD
COSM1207069	p.Arg262Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122892314G>A	NCI-TCGA Cosmic
rs752508997	p.Tyr266His	missense variant	-	NC_000004.12:g.122892325T>C	ExAC,gnomAD
rs755800634	p.Gly269Glu	missense variant	-	NC_000004.12:g.122892335G>A	ExAC,gnomAD
rs1199964600	p.Ser270Phe	missense variant	-	NC_000004.12:g.122892338C>T	gnomAD
rs749531276	p.Gly273Glu	missense variant	-	NC_000004.12:g.122892347G>A	ExAC,gnomAD
rs1487654289	p.Pro274Leu	missense variant	-	NC_000004.12:g.122892350C>T	TOPMed
rs1188387338	p.Gln276His	missense variant	-	NC_000004.12:g.122892357G>C	gnomAD
COSM4121863	p.Gln276Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122892355C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Lys277Thr	missense variant	-	NC_000004.12:g.122892359A>C	NCI-TCGA
rs1237118268	p.Met284Thr	missense variant	-	NC_000004.12:g.122892380T>C	TOPMed
rs765660062	p.Met284Val	missense variant	-	NC_000004.12:g.122892379A>G	TOPMed,gnomAD
rs1346242368	p.Met284Ile	missense variant	-	NC_000004.12:g.122892381G>A	TOPMed
rs779177648	p.Ser285Cys	missense variant	-	NC_000004.12:g.122892383C>G	ExAC,TOPMed,gnomAD
rs779177648	p.Ser285Phe	missense variant	-	NC_000004.12:g.122892383C>T	ExAC,TOPMed,gnomAD
rs1215455721	p.Ala286Thr	missense variant	-	NC_000004.12:g.122892385G>A	TOPMed
rs745924109	p.Lys287Thr	missense variant	-	NC_000004.12:g.122892389A>C	ExAC,TOPMed
rs1367982250	p.Lys287Gln	missense variant	-	NC_000004.12:g.122892388A>C	gnomAD
COSM74661	p.Ser288Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000004.12:g.122892393C>G	NCI-TCGA Cosmic

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001080	Achondroplasia	disease	BEFREE
C0001175	Acquired Immunodeficiency Syndrome	group	BEFREE
C0001193	Apert syndrome	disease	BEFREE
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001430	Adenoma	group	BEFREE
C0001815	Primary Myelofibrosis	disease	BEFREE;LHGDN
C0001849	AIDS Dementia Complex	disease	BEFREE
C0002395	Alzheimer's Disease	disease	BEFREE
C0002726	Amyloidosis	disease	BEFREE
C0002736	Amyotrophic Lateral Sclerosis	disease	BEFREE
C0002793	Anaplasia	disease	BEFREE
C0002871	Anemia	disease	LHGDN
C0002940	Aneurysm	phenotype	BEFREE
C0003850	Arteriosclerosis	disease	BEFREE
C0003857	Congenital arteriovenous malformation	disease	BEFREE
C0003864	Arthritis	disease	BEFREE;LHGDN
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004096	Asthma	disease	BEFREE;LHGDN
C0004114	Astrocytoma	disease	BEFREE
C0004153	Atherosclerosis	disease	BEFREE
C0004565	Melanoma, B16	disease	BEFREE
C0004623	Bacterial Infections	group	BEFREE
C0004763	Barrett Esophagus	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005686	Urinary Bladder Diseases	group	RGD
C0005695	Bladder Neoplasm	group	BEFREE;LHGDN
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007095	Carcinoid Tumor	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE;LHGDN
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0007766	Intracranial Aneurysm	disease	BEFREE
C0007785	Cerebral Infarction	disease	LHGDN
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008373	Cholesteatoma	disease	LHGDN
C0008479	Chondrosarcoma	disease	BEFREE
C0008487	Chordoma	disease	BEFREE
C0008497	Choriocarcinoma	disease	BEFREE
C0008924	Cleft upper lip	disease	CTD_human
C0008925	Cleft Palate	disease	CTD_human
C0009171	Cocaine Abuse	disease	CTD_human
C0009324	Ulcerative Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009404	Colorectal Neoplasms	group	LHGDN
C0009952	Febrile Convulsions	disease	BEFREE
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0010278	Craniosynostosis	disease	BEFREE
C0010346	Crohn Disease	disease	BEFREE
C0010606	Adenoid Cystic Carcinoma	disease	LHGDN
C0010709	Cyst	phenotype	BEFREE
C0010823	Cytomegalovirus Infections	group	BEFREE
C0011127	Pressure Ulcer	disease	RGD
C0011570	Mental Depression	disease	BEFREE
C0011573	Endogenous depression	disease	CTD_human
C0011581	Depressive disorder	disease	BEFREE;CTD_human
C0011644	Scleroderma	disease	BEFREE
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0011854	Diabetes Mellitus, Insulin-Dependent	disease	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE;LHGDN
C0011875	Diabetic Angiopathies	disease	BEFREE
C0011881	Diabetic Nephropathy	disease	BEFREE
C0011884	Diabetic Retinopathy	disease	LHGDN;RGD
C0013312	Dupuytren Contracture	disease	BEFREE
C0013336	Dwarfism	disease	BEFREE
C0014038	Encephalitis	disease	BEFREE
C0014175	Endometriosis	disease	BEFREE
C0014549	Tonic-Clonic Epilepsy	disease	CTD_human
C0014859	Esophageal Neoplasms	group	BEFREE;LHGDN
C0015302	External exotoses	disease	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0016059	Fibrosis	phenotype	LHGDN
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;CTD_human;LHGDN
C0017639	Gliosis	phenotype	CTD_human
C0018553	Hamartoma Syndrome, Multiple	disease	BEFREE
C0018799	Heart Diseases	group	BEFREE
C0018800	Cardiomegaly	phenotype	CTD_human
C0018801	Heart failure	disease	LHGDN
C0018916	Hemangioma	disease	BEFREE
C0019061	Hemolytic-Uremic Syndrome	disease	BEFREE
C0019284	Diaphragmatic Hernia	phenotype	CTD_human
C0019348	Herpes Simplex Infections	group	BEFREE
C0019693	HIV Infections	group	BEFREE
C0019829	Hodgkin Disease	disease	BEFREE;LHGDN
C0020179	Huntington Disease	disease	BEFREE
C0020443	Hypercholesterolemia	disease	BEFREE
C0020456	Hyperglycemia	disease	BEFREE
C0020507	Hyperplasia	phenotype	LHGDN
C0020538	Hypertensive disease	group	BEFREE;RGD
C0020542	Pulmonary Hypertension	phenotype	RGD
C0021051	Immunologic Deficiency Syndromes	group	BEFREE
C0021368	Inflammation	phenotype	CTD_human;LHGDN
C0021390	Inflammatory Bowel Diseases	group	BEFREE;LHGDN
C0021775	Intermittent Claudication	phenotype	BEFREE
C0021841	Intestinal Neoplasms	group	BEFREE
C0022333	Jacksonian Seizure	disease	CTD_human
C0022408	Arthropathy	group	BEFREE
C0022548	Keloid	phenotype	BEFREE
C0022658	Kidney Diseases	group	BEFREE;CTD_human
C0022661	Kidney Failure, Chronic	disease	BEFREE
C0023267	Fibroid Tumor	group	BEFREE;LHGDN
C0023269	leiomyosarcoma	disease	BEFREE
C0023418	leukemia	disease	BEFREE;LHGDN
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE;LHGDN
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE;LHGDN
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023531	Leukoplakia	disease	BEFREE
C0023890	Liver Cirrhosis	disease	BEFREE;CTD_human;LHGDN
C0023893	Liver Cirrhosis, Experimental	disease	CTD_human
C0023903	Liver neoplasms	group	BEFREE
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE
C0024299	Lymphoma	group	BEFREE;LHGDN
C0024305	Lymphoma, Non-Hodgkin	disease	BEFREE;LHGDN
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0024814	Marinesco-Sjogren syndrome	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025193	Melancholia	disease	CTD_human
C0025202	melanoma	disease	BEFREE;LHGDN
C0025267	Multiple Endocrine Neoplasia Type 1	disease	BEFREE
C0025286	Meningioma	disease	BEFREE;LHGDN
C0025312	Meningomyelocele	disease	BEFREE
C0025500	Mesothelioma	disease	BEFREE;CTD_human;LHGDN
C0026010	Microphthalmos	disease	BEFREE
C0026470	Monoclonal Gammopathy of Undetermined Significance	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE;LHGDN
C0026948	Mycosis Fungoides	group	BEFREE
C0026987	Myelofibrosis	disease	BEFREE
C0027022	Myeloproliferative disease	group	LHGDN
C0027051	Myocardial Infarction	disease	BEFREE
C0027086	Myoma	disease	LHGDN
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0027651	Neoplasms	group	BEFREE
C0027662	Multiple Endocrine Neoplasia	disease	BEFREE
C0027697	Nephritis	disease	LHGDN
C0027707	Nephritis, Interstitial	disease	BEFREE
C0027726	Nephrotic Syndrome	group	CTD_human
C0027746	Nerve Degeneration	phenotype	CTD_human
C0027819	Neuroblastoma	group	BEFREE
C0027830	neurofibroma	disease	BEFREE
C0027859	Acoustic Neuroma	disease	BEFREE
C0027960	Nevus	disease	BEFREE
C0027962	Melanocytic nevus	disease	BEFREE
C0028754	Obesity	disease	BEFREE
C0028945	oligodendroglioma	disease	BEFREE
C0029172	Oral Submucous Fibrosis	disease	BEFREE;CTD_human;LHGDN
C0029227	Delirium, Dementia, Amnestic, Cognitive Disorders	group	BEFREE
C0029401	Osteitis Deformans	disease	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029442	Osteomalacia	disease	BEFREE
C0029453	Osteopenia	disease	BEFREE
C0029456	Osteoporosis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE;LHGDN
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	LHGDN
C0030312	Pancytopenia	disease	BEFREE
C0030567	Parkinson Disease	disease	BEFREE
C0031030	Periapical Periodontitis	disease	CTD_human;LHGDN
C0032000	Pituitary Adenoma	disease	BEFREE
C0032019	Pituitary Neoplasms	group	BEFREE
C0032227	Pleural effusion disorder	group	BEFREE
C0032927	Precancerous Conditions	group	BEFREE
C0032969	Pregnancy in Diabetics	phenotype	BEFREE
C0033054	Prenatal Exposure Delayed Effects	disease	CTD_human
C0033375	Prolactinoma	disease	BEFREE
C0033575	Prostatic Diseases	group	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE;CTD_human;LHGDN
C0034069	Pulmonary Fibrosis	disease	BEFREE;CTD_human
C0034543	Radicular Cyst	disease	LHGDN
C0035126	Reperfusion Injury	disease	CTD_human
C0035309	Retinal Diseases	group	BEFREE
C0035328	Retinal Vein Occlusion	disease	RGD
C0035334	Retinitis Pigmentosa	disease	BEFREE
C0035412	Rhabdomyosarcoma	disease	BEFREE
C0036220	Kaposi Sarcoma	disease	BEFREE
C0036280	Burn scar	phenotype	BEFREE
C0036341	Schizophrenia	disease	PSYGENET
C0036421	Systemic Scleroderma	disease	BEFREE;LHGDN
C0036439	Scoliosis, unspecified	phenotype	LHGDN
C0036572	Seizures	phenotype	BEFREE;CTD_human
C0037284	Skin lesion	group	BEFREE
C0037579	Soft Tissue Neoplasms	group	BEFREE
C0038358	Gastric ulcer	disease	BEFREE
C0039101	synovial sarcoma	disease	BEFREE
C0039538	Teratoma	disease	BEFREE
C0039743	Thanatophoric Dysplasia	disease	BEFREE
C0040028	Thrombocythemia, Essential	disease	CTD_human
C0040136	Thyroid Neoplasm	disease	BEFREE;LHGDN
C0040262	Tinea Versicolor	disease	BEFREE
C0040997	Trigeminal Neuralgia	disease	BEFREE
C0041349	Nephritis, Tubulointerstitial	disease	BEFREE
C0041582	Ulcer	disease	BEFREE
C0041696	Unipolar Depression	disease	BEFREE;CTD_human
C0042133	Uterine Fibroids	group	BEFREE
C0042373	Vascular Diseases	group	BEFREE
C0042769	Virus Diseases	group	BEFREE
C0042900	Vitiligo	disease	BEFREE
C0043250	Injury wounds	group	CTD_human
C0043251	Wounds and Injuries	group	CTD_human
C0079731	B-Cell Lymphomas	group	BEFREE
C0080032	Pleural Effusion, Malignant	disease	BEFREE
C0085096	Peripheral Vascular Diseases	group	BEFREE
C0085109	Corneal Neovascularization	disease	BEFREE;CTD_human;LHGDN
C0085110	Severe Combined Immunodeficiency	disease	BEFREE
C0085207	Gestational Diabetes	phenotype	CTD_human
C0085404	POEMS Syndrome	disease	BEFREE
C0085411	Angiodysplasia	disease	BEFREE
C0085682	Hypophosphatemia	disease	BEFREE
C0085742	Injuries, Acute Brain	group	CTD_human
C0085786	Hamman-Rich syndrome	disease	BEFREE;CTD_human
C0086133	Depressive Syndrome	disease	CTD_human
C0149521	Pancreatitis, Chronic	disease	BEFREE
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0149958	Complex partial seizures	disease	CTD_human
C0151744	Myocardial Ischemia	disease	BEFREE;CTD_human
C0151779	Cutaneous Melanoma	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0152171	Idiopathic pulmonary hypertension	disease	BEFREE
C0153633	Malignant neoplasm of brain	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0154830	Proliferative diabetic retinopathy	disease	BEFREE
C0155094	Corneal pannus	disease	BEFREE
C0158646	Cleft palate with cleft lip	disease	BEFREE
C0162678	Neurofibromatoses	group	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206062	Lung Diseases, Interstitial	group	BEFREE
C0206656	Embryonal Rhabdomyosarcoma	disease	BEFREE
C0206659	Embryonal Carcinoma	disease	BEFREE
C0206682	Follicular thyroid carcinoma	disease	BEFREE
C0206686	Adrenocortical carcinoma	disease	BEFREE
C0206708	Cervical Intraepithelial Neoplasia	disease	BEFREE
C0206727	Nerve Sheath Tumors	group	BEFREE
C0220620	Gastrointestinal Carcinoid Tumor	disease	BEFREE
C0220633	Uveal melanoma	disease	BEFREE
C0220658	Pfeiffer Syndrome	disease	BEFREE
C0220756	Niemann-Pick Disease, Type C	disease	BEFREE
C0221052	Chronic berylliosis	disease	BEFREE
C0234533	Generalized seizures	disease	CTD_human
C0234535	Seizures, Clonic	disease	CTD_human
C0235522	Disorder of vein	group	BEFREE
C0235874	Disease Exacerbation	phenotype	CTD_human
C0235974	Pancreatic carcinoma	disease	BEFREE
C0236736	Cocaine-Related Disorders	group	CTD_human
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0238288	Muscular Dystrophy, Facioscapulohumeral	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE;CTD_human
C0242350	Erectile dysfunction	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0242383	Age related macular degeneration	disease	BEFREE
C0243038	Carcinoma, Lewis Lung	disease	BEFREE
C0259783	mixed gliomas	disease	CTD_human
C0264694	Chronic myocardial ischemia	disease	BEFREE
C0267370	Angiodysplasia of colon	disease	BEFREE
C0268351	Cutis Laxa, Autosomal Recessive, Type I	disease	BEFREE
C0268800	Simple renal cyst	disease	BEFREE
C0270611	Brain Injuries	group	CTD_human
C0270824	Visual seizure	disease	CTD_human
C0270844	Tonic Seizures	phenotype	CTD_human
C0270846	Epileptic drop attack	disease	CTD_human
C0272945	Brain Lacerations	disease	CTD_human
C0276496	Familial Alzheimer Disease (FAD)	disease	BEFREE
C0276535	AIDS with Kaposi's sarcoma	disease	BEFREE
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0278883	Metastatic melanoma	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279628	Adenocarcinoma Of Esophagus	disease	BEFREE
C0279746	Adenocarcinoma of salivary gland	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0281361	Adenocarcinoma of pancreas	disease	BEFREE
C0282126	Depression, Neurotic	disease	CTD_human
C0302592	Cervix carcinoma	disease	BEFREE
C0332877	Congenital premature fusion	disease	BEFREE
C0333047	Recession	phenotype	BEFREE
C0333293	Healing ulcer	phenotype	BEFREE
C0334579	Anaplastic astrocytoma	disease	BEFREE
C0341858	Endometriosis of uterus	disease	BEFREE
C0345967	Malignant mesothelioma	disease	BEFREE
C0346388	Malignant melanoma of choroid	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0349529	Gastric Carcinoid Tumor	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE;CTD_human
C0376544	Hematopoietic Neoplasms	group	BEFREE
C0376545	Hematologic Neoplasms	group	BEFREE
C0392400	Diffuse malignant mesothelioma	disease	BEFREE
C0393953	Anterior Cerebral Circulation Infarction	disease	CTD_human
C0398650	Immune thrombocytopenic purpura	disease	LHGDN
C0422850	Seizures, Somatosensory	phenotype	CTD_human
C0422852	Seizures, Auditory	phenotype	CTD_human
C0422853	Olfactory seizure	disease	CTD_human
C0422854	Gustatory seizure	phenotype	CTD_human
C0422855	Vertiginous seizure	disease	CTD_human
C0424295	Hyperactive behavior	phenotype	BEFREE
C0452047	Brain Injuries, Focal	group	CTD_human
C0476089	Endometrial Carcinoma	disease	BEFREE
C0494475	Tonic - clonic seizures	disease	CTD_human
C0521158	Recurrent tumor	phenotype	BEFREE
C0524686	Periodontitis, Acute Nonsuppurative	disease	CTD_human
C0524910	Hepatitis C, Chronic	disease	LHGDN
C0525045	Mood Disorders	group	BEFREE;PSYGENET
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549357	Abdominal adhesions	phenotype	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553580	Ewings sarcoma	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE;CTD_human
C0578022	Finding of body mass index	phenotype	GWASCAT
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0600427	Cocaine Dependence	disease	CTD_human
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0677898	invasive cancer	phenotype	BEFREE
C0677936	Refractory cancer	phenotype	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0684337	Ewings sarcoma-primitive neuroectodermal tumor (PNET)	disease	BEFREE
C0684830	Secondary malignant neoplasm of axilla	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0687140	Hemangioma of skin	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0740391	Middle Cerebral Artery Occlusion	phenotype	BEFREE
C0740457	Malignant neoplasm of kidney	disease	BEFREE
C0751056	Non-epileptic convulsion	phenotype	CTD_human
C0751110	Single Seizure	disease	CTD_human
C0751117	Cryptogenic Tonic-Clonic Epilepsy	disease	CTD_human
C0751118	Epilepsy, Tonic-Clonic, Familial	disease	CTD_human
C0751119	Epilepsy, Tonic-Clonic, Symptomatic	disease	CTD_human
C0751123	Atonic Absence Seizures	disease	CTD_human
C0751396	Well Differentiated Oligodendroglioma	disease	BEFREE
C0751494	Convulsive Seizures	phenotype	CTD_human
C0751495	Seizures, Focal	phenotype	CTD_human
C0751496	Seizures, Sensory	phenotype	CTD_human
C0751952	Anterior Circulation Brain Infarction	disease	CTD_human
C0751953	Brain Infarction, Posterior Circulation	disease	CTD_human
C0751954	Venous Infarction, Brain	disease	CTD_human
C0751955	Brain Infarction	disease	CTD_human
C0751956	Acute Cerebrovascular Accidents	disease	BEFREE
C0851887	Adenoviral infections	group	BEFREE
C0854723	Retinal Dystrophies	group	BEFREE
C0856169	Endothelial dysfunction	phenotype	BEFREE
C0877849	Askin's tumor	disease	BEFREE
C0887833	Carcinoma, Pancreatic Ductal	disease	BEFREE
C0919267	ovarian neoplasm	disease	BEFREE
C0936223	Metastatic Prostate Carcinoma	disease	BEFREE
C0948008	Ischemic stroke	disease	BEFREE
C0948216	Ovarian adenocarcinoma	disease	BEFREE
C0948249	Femoral artery occlusion	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1145670	Respiratory Failure	disease	BEFREE
C1153706	Endometrial adenocarcinoma	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1176475	Ductal Carcinoma	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1266029	Enterochromaffin-like cell carcinoid	disease	BEFREE
C1269683	Major Depressive Disorder	disease	BEFREE
C1282496	Metastasis from malignant tumor of prostate	disease	BEFREE
C1292753	Primary Effusion Lymphoma	disease	BEFREE;LHGDN
C1300257	Thanatophoric dysplasia, type 2	disease	BEFREE
C1301700	Cardiovascular morbidity	phenotype	BEFREE
C1305855	Body mass index	phenotype	GWASCAT
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1333944	Paraganglioma of head and neck	disease	BEFREE
C1333987	Hereditary Glomangioma	disease	BEFREE
C1334647	Maxillary Sinus Squamous Cell Carcinoma	disease	BEFREE
C1334687	Megakaryocytic Neoplasm	disease	BEFREE
C1336527	Carcinoma of urinary bladder, superficial	disease	BEFREE
C1337013	Differentiated Thyroid Gland Carcinoma	disease	BEFREE
C1367536	Nasopharyngeal Angiofibroma	disease	BEFREE
C1368683	Epithelioma	disease	BEFREE
C1383860	Cardiac Hypertrophy	phenotype	CTD_human
C1456781	Benign melanocytic nevus	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1510885	Angiogenic Switch	disease	BEFREE
C1511789	Desmoplastic	disease	BEFREE
C1514422	Glioblastoma, IDH-Wildtype	disease	BEFREE
C1519176	Salivary Gland Pleomorphic Adenoma	disease	BEFREE
C1519666	Tumor-Associated Vasculature	phenotype	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1522378	Leukemia, Large Granular Lymphocytic	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1531608	Smoldering myeloma	disease	BEFREE
C1559154	Rash and Dermatitis Adverse Event Associated with Chemoradiation	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1691228	Cystic Kidney Diseases	group	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1704436	Peripheral Arterial Diseases	group	BEFREE
C1800706	Idiopathic Pulmonary Fibrosis	disease	BEFREE
C1833340	Synostotic Posterior Plagiocephaly	disease	BEFREE
C1837218	Cleft palate, isolated	disease	CTD_human
C1847835	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)	disease	BEFREE
C1855179	CATARACT, ANTERIOR POLAR	disease	BEFREE
C1861305	TARSAL-CARPAL COALITION SYNDROME	disease	BEFREE
C1868678	THANATOPHORIC DYSPLASIA, TYPE I (disorder)	disease	BEFREE
C1883486	Uterine Corpus Cancer	disease	BEFREE
C1955690	Extranodal marginal zone B-cell lymphoma	disease	BEFREE
C1956089	Osteophyte	disease	BEFREE
C1998028	Photoreceptor degeneration	disease	BEFREE
C2145472	Urothelial Carcinoma	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;LHGDN
C2316810	Chronic kidney disease stage 5	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C2937421	Prostatic Hyperplasia	disease	LHGDN
C2945695	Limb ischemia	disease	BEFREE
C3203102	Idiopathic pulmonary arterial hypertension	disease	BEFREE
C3263723	Traumatic injury	group	CTD_human
C3281247	BENT BONE DYSPLASIA SYNDROME	disease	BEFREE
C3489628	Thrombocytosis, Autosomal Dominant	disease	CTD_human
C3495874	Nonepileptic Seizures	disease	CTD_human
C3536893	Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	disease	BEFREE
C3536983	Familial Hypophosphatemic Rickets	disease	BEFREE
C3536984	Vitamin D-Resistant Rickets, X-Linked	disease	BEFREE
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3540852	Rickets, X-Linked Hypophosphatemic	disease	BEFREE
C3811653	Experimental Organism Basal Cell Carcinoma	phenotype	BEFREE
C3887486	Interstitial lung fibrosis	phenotype	BEFREE
C3887499	Renal cyst	phenotype	BEFREE
C3887640	Astrocytosis	phenotype	CTD_human
C3887650	Adult Rickets	disease	BEFREE
C4041080	Neurocognitive Disorders	group	BEFREE
C4046002	Research-Related Injuries	group	CTD_human
C4048158	Convulsions	phenotype	CTD_human
C4048328	cervical cancer	disease	BEFREE
C4316903	Absence Seizures	phenotype	CTD_human
C4317109	Epileptic Seizures	disease	CTD_human
C4317123	Myoclonic Seizures	phenotype	CTD_human
C4505436	Generalized Absence Seizures	disease	CTD_human

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005104	fibroblast growth factor receptor binding	IPI
GO:0005125	cytokine activity	IDA
GO:0005178	integrin binding	IDA
GO:0005515	protein binding	IPI
GO:0008083	growth factor activity	IDA
GO:0008201	heparin binding	IEA
GO:0019956	chemokine binding	IPI
GO:0030374	nuclear receptor transcription coactivator activity	IDA
GO:0042056	chemoattractant activity	IDA
GO:0042802	identical protein binding	IPI
GO:0090722	receptor-receptor interaction	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000165	MAPK cascade	TAS
GO:0000187	activation of MAPK activity	TAS
GO:0001658	branching involved in ureteric bud morphogenesis	IDA
GO:0001938	positive regulation of endothelial cell proliferation	IDA
GO:0001938	positive regulation of endothelial cell proliferation	IMP
GO:0002042	cell migration involved in sprouting angiogenesis	IDA
GO:0002042	cell migration involved in sprouting angiogenesis	IGI
GO:0006661	phosphatidylinositol biosynthetic process	IDA
GO:0006935	chemotaxis	TAS
GO:0007165	signal transduction	NAS
GO:0007265	Ras protein signal transduction	TAS
GO:0007399	nervous system development	TAS
GO:0008284	positive regulation of cell population proliferation	IDA
GO:0008284	positive regulation of cell population proliferation	IGI
GO:0008543	fibroblast growth factor receptor signaling pathway	IPI
GO:0008543	fibroblast growth factor receptor signaling pathway	IDA
GO:0008543	fibroblast growth factor receptor signaling pathway	IGI
GO:0008543	fibroblast growth factor receptor signaling pathway	TAS
GO:0009887	animal organ morphogenesis	TAS
GO:0010764	negative regulation of fibroblast migration	IDA
GO:0010863	positive regulation of phospholipase C activity	IDA
GO:0014843	growth factor dependent regulation of skeletal muscle satellite cell proliferation	IMP
GO:0019221	cytokine-mediated signaling pathway	TAS
GO:0030198	extracellular matrix organization	TAS
GO:0030214	hyaluronan catabolic process	IDA
GO:0032958	inositol phosphate biosynthetic process	IDA
GO:0035019	somatic stem cell population maintenance	TAS
GO:0038001	paracrine signaling	ISS
GO:0042060	wound healing	IDA
GO:0042060	wound healing	TAS
GO:0042660	positive regulation of cell fate specification	IDA
GO:0043406	positive regulation of MAP kinase activity	IDA
GO:0043536	positive regulation of blood vessel endothelial cell migration	IDA
GO:0043536	positive regulation of blood vessel endothelial cell migration	IGI
GO:0043537	negative regulation of blood vessel endothelial cell migration	IDA
GO:0043552	positive regulation of phosphatidylinositol 3-kinase activity	IDA
GO:0045765	regulation of angiogenesis	TAS
GO:0045766	positive regulation of angiogenesis	IDA
GO:0045766	positive regulation of angiogenesis	IGI
GO:0045893	positive regulation of transcription, DNA-templated	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	IDA
GO:0048598	embryonic morphogenesis	TAS
GO:0050918	positive chemotaxis	IEA
GO:0051209	release of sequestered calcium ion into cytosol	IDA
GO:0051781	positive regulation of cell division	IEA
GO:0051897	positive regulation of protein kinase B signaling	TAS
GO:0060045	positive regulation of cardiac muscle cell proliferation	IDA
GO:0060548	negative regulation of cell death	IDA
GO:0060591	chondroblast differentiation	IDA
GO:0061045	negative regulation of wound healing	IDA
GO:0070374	positive regulation of ERK1 and ERK2 cascade	IDA
GO:0072089	stem cell proliferation	NAS
GO:0090050	positive regulation of cell migration involved in sprouting angiogenesis	IDA
GO:1903672	positive regulation of sprouting angiogenesis	IDA
GO:1903672	positive regulation of sprouting angiogenesis	IMP
GO:1904707	positive regulation of vascular smooth muscle cell proliferation	IGI
GO:1905564	positive regulation of vascular endothelial cell proliferation	IGI
GO:2000544	regulation of endothelial cell chemotaxis to fibroblast growth factor	IDA
GO:2000546	positive regulation of endothelial cell chemotaxis to fibroblast growth factor	IDA
GO:2000573	positive regulation of DNA biosynthetic process	IDA
GO:2000573	positive regulation of DNA biosynthetic process	IGI
GO:2001028	positive regulation of endothelial cell chemotaxis	IGI

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IDA
GO:0005623	cell	IEA
GO:0005634	nucleus	IEA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1226099	Signaling by FGFR in disease	IEA
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-1474244	Extracellular matrix organization	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-1643685	Disease	IEA
R-HSA-168256	Immune System	TAS
R-HSA-1839122	Signaling by activated point mutants of FGFR1	TAS
R-HSA-1839124	FGFR1 mutant receptor activation	TAS
R-HSA-1839126	FGFR2 mutant receptor activation	TAS
R-HSA-1839126	FGFR2 mutant receptor activation	IEA
R-HSA-1839130	Signaling by activated point mutants of FGFR3	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-190239	FGFR3 ligand binding and activation	TAS
R-HSA-190241	FGFR2 ligand binding and activation	TAS
R-HSA-190242	FGFR1 ligand binding and activation	TAS
R-HSA-190322	FGFR4 ligand binding and activation	TAS
R-HSA-190370	FGFR1b ligand binding and activation	TAS
R-HSA-190372	FGFR3c ligand binding and activation	TAS
R-HSA-190373	FGFR1c ligand binding and activation	TAS
R-HSA-190375	FGFR2c ligand binding and activation	TAS
R-HSA-190377	FGFR2b ligand binding and activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-2033514	FGFR3 mutant receptor activation	TAS
R-HSA-2033519	Activated point mutants of FGFR2	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	TAS
R-HSA-3000170	Syndecan interactions	TAS
R-HSA-3000171	Non-integrin membrane-ECM interactions	TAS
R-HSA-449147	Signaling by Interleukins	TAS
R-HSA-452723	Transcriptional regulation of pluripotent stem cells	TAS
R-HSA-5654219	Phospholipase C-mediated cascade: FGFR1	TAS
R-HSA-5654221	Phospholipase C-mediated cascade; FGFR2	TAS
R-HSA-5654227	Phospholipase C-mediated cascade; FGFR3	TAS
R-HSA-5654228	Phospholipase C-mediated cascade; FGFR4	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654688	SHC-mediated cascade:FGFR1	TAS
R-HSA-5654689	PI-3K cascade:FGFR1	TAS
R-HSA-5654693	FRS-mediated FGFR1 signaling	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654704	SHC-mediated cascade:FGFR3	TAS
R-HSA-5654706	FRS-mediated FGFR3 signaling	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654710	PI-3K cascade:FGFR3	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654726	Negative regulation of FGFR1 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654732	Negative regulation of FGFR3 signaling	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	IEA
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5658623	FGFRL1 modulation of FGFR1 signaling	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663202	Diseases of signal transduction	IEA
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-8851708	Signaling by FGFR2 IIIa TM	IEA
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9607240	FLT3 Signaling	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
D019813	1,2-Dimethylhydrazine	1,2-Dimethylhydrazine results in increased expression of FGF2 protein	29879413
D019813	1,2-Dimethylhydrazine	trans-3-(4'-hydroxyphenyl)-2-propenoic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of FGF2 protein]	29879413
C049325	1,2-dithiol-3-thione	1,2-dithiol-3-thione results in increased expression of FGF2 mRNA	19162173
C046782	14,15-epoxy-5,8,11-eicosatrienoic acid	14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein	16286479
D019307	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
C036535	1,6-bis(cyclohexyloximinocarbonyl)hexane	1,6-bis(cyclohexyloximinocarbonyl)hexane inhibits the reaction [FGF2 protein results in increased phosphorylation of GAP43 protein]	9852580
D015056	1-Methyl-3-isobutylxanthine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA	29698629
D015056	1-Methyl-3-isobutylxanthine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA	29698629
D015056	1-Methyl-3-isobutylxanthine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA	29698629
D015056	1-Methyl-3-isobutylxanthine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA	29698629
D015056	1-Methyl-3-isobutylxanthine	boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D015056	1-Methyl-3-isobutylxanthine	[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein	28285642
D015056	1-Methyl-3-isobutylxanthine	sodium pentaborate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D015632	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FGF2 mRNA	28801915
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of FGF2 mRNA	25234470
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased methylation of FGF2 gene	28801915
D015655	1-Methyl-4-phenylpyridinium	FGF2 protein results in decreased susceptibility to 1-Methyl-4-phenylpyridinium	7882977
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF2 mRNA	28329830
D015058	1-Naphthylisothiocyanate	[1-Naphthylisothiocyanate co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
C518874	1-propyl-8-(4-sulfophenyl)xanthine	1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [BAY 60-6583 results in increased expression of FGF2 protein]	27590504
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[EGF protein co-treated with FGF2 protein] results in increased phosphorylation of and results in increased activity of MAPK7 protein]	23564643
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased activity of HIF1A protein]	15631803
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	15631803
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	15631803
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased expression of PLAU mRNA]	9442043
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased expression of BDNF mRNA]	16269011
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of CREB1 protein]	16269011
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	16269011
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]	11742803
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased activity of MAPK1 protein]	8878442
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased activity of MAPK3 protein]	8878442
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased susceptibility to FGF2 protein	8878442
C046728	2,2'-azobis(2-amidinopropane)	2,2'-azobis(2-amidinopropane) results in decreased expression of FGF2 mRNA	26177723
C014211	2,3,7,8-tetrachlorodibenzofuran	2,3,7,8-tetrachlorodibenzofuran results in decreased expression of FGF2 mRNA	21724226
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased expression of and results in increased activity of HIF1A protein]	15631803
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	15631803
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of FGF2 protein	29129800
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	16303940
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased stability of and results in increased expression of COL1A1 protein]	16303940
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased stability of and results in increased expression of COL1A2 protein]	16303940
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]	11742803
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[FGF2 protein binds to and results in increased activity of FGFR4 protein] which results in increased phosphorylation of MAPK1 protein]	11336793
C023514	2,6-dinitrotoluene	2,6-dinitrotoluene results in increased expression of FGF2 mRNA	20406850
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FGF2 mRNA]	23625689
C511621	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide results in decreased expression of FGF2 mRNA	23625689
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of FGF2 mRNA	23196670
C082182	3,5-diiodothyropropionic acid	3,5-diiodothyropropionic acid results in increased expression of FGF2 protein	16384862
C553471	3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one	3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one affects the susceptibility to FGF2 protein	19199859
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Sodium Chloride results in increased secretion of FGF2 protein]	26800359
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF2 mRNA	27188386
C075773	4-phenylbutyric acid	4-phenylbutyric acid results in decreased expression of FGF2 mRNA	14583596
C545140	6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine	[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Nitric Oxide	19539746
C545140	6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine	[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Reactive Oxygen Species	19539746
C545140	6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine	[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased activity of NOS2 protein	19539746
C545140	6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Nitric Oxide]	19539746
C545140	6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Reactive Oxygen Species]	19539746
D015120	6-Aminonicotinamide	6-Aminonicotinamide results in increased expression of FGF2 protein	12898533
D015120	6-Aminonicotinamide	IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein]	12898533
C496492	abrine	abrine results in increased expression of FGF2 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of FGF2 mRNA	21135413
D000082	Acetaminophen	FLT1 protein affects the reaction [Acetaminophen results in increased expression of FGF2 mRNA]	21135413
D000082	Acetaminophen	Acetaminophen results in increased activity of FGF2 protein	25858767
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]	19176594
D000111	Acetylcysteine	Acetylcysteine results in decreased expression of FGF2 mRNA	16084531
D000117	Acetylglucosamine	Acetylglucosamine analog promotes the reaction [FGF2 protein binds to FGFR1 protein]	12440867
D020106	Acrylamide	Acrylamide analog promotes the reaction [FGF2 protein binds to FGFR1 protein]	12440867
D020106	Acrylamide	Acrylamide analog inhibits the reaction [Trifluoroacetic Acid results in increased degradation of FGF2 protein]	14733594
D020106	Acrylamide	Acrylamide analog promotes the reaction [FGF2 protein binds to FGF2 protein]	14733594
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of FGF2 mRNA	27153756
D000420	Albuterol	Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]	18076728
D000420	Albuterol	Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]	18076728
D000420	Albuterol	Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]	18076728
D000420	Albuterol	[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]	18076728
C006453	alliin	alliin results in decreased activity of FGF2 protein	16351512
C006453	alliin	Ascorbic Acid promotes the reaction [alliin results in decreased activity of FGF2 protein]	16351512
C006453	alliin	Vitamin E promotes the reaction [alliin results in decreased activity of FGF2 protein]	16351512
C006453	alliin	alliin promotes the reaction [FGF2 protein results in increased expression of TP53 protein]	16351512
C006453	alliin	alliin results in decreased secretion of FGF2 protein	16351512
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	20876236
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	20876236
D000538	Aluminum Silicates	Aluminum Silicates results in increased secretion of FGF2 protein	16335828
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of FGF2 mRNA	16483693
D000661	Amphetamine	Amphetamine affects the expression of FGF2 protein	10854759
D000661	Amphetamine	Amphetamine results in increased expression of FGF2 protein	16338078
D047310	Apigenin	Apigenin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D001149	Arsenates	Arsenates results in increased expression of FGF2 mRNA	15345372
D001151	Arsenic	Arsenic affects the methylation of FGF2 gene	25304211
D001151	Arsenic	Arsenic results in decreased expression of FGF2 mRNA	24019935
D000077237	Arsenic Trioxide	Arsenic Trioxide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	15723287
D000077237	Arsenic Trioxide	Arsenic Trioxide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	15723287
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of FGF2 mRNA	22521957
C015001	arsenite	arsenite results in increased expression of FGF2 mRNA	15345372
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite affects the expression of FGF2 mRNA	17331233
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of FGF2 mRNA	18687144
D017632	Asbestos, Serpentine	[Asbestos, Serpentine results in increased secretion of IL1B protein] which results in increased secretion of FGF2 protein	23017228
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in increased expression of FGF2 mRNA	9400719
D001205	Ascorbic Acid	Ascorbic Acid promotes the reaction [alliin results in decreased activity of FGF2 protein]	16351512
D001397	Azoxymethane	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA	29950665
C028559	bathocuproine sulfonate	bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	22842628
C028559	bathocuproine sulfonate	bathocuproine sulfonate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	22842628
C518875	BAY 60-6583	1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [BAY 60-6583 results in increased expression of FGF2 protein]	27590504
C518875	BAY 60-6583	[BAY 60-6583 co-treated with cobaltous chloride] results in increased expression of FGF2 protein	27590504
C518875	BAY 60-6583	BAY 60-6583 results in increased expression of FGF2 protein	27590504
D001507	Beclomethasone	Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]	18076728
D001507	Beclomethasone	Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]	18076728
D001507	Beclomethasone	Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]	18076728
D001507	Beclomethasone	[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]	18076728
D001507	Beclomethasone	[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]	18076728
D001507	Beclomethasone	Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]	18076728
D001507	Beclomethasone	Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]	18076728
D001507	Beclomethasone	Beclomethasone results in decreased activity of FGF2 protein	18076728
D001507	Beclomethasone	Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]	18076728
D001507	Beclomethasone	Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]	18076728
D001507	Beclomethasone	Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]	18076728
D001548	Benzalkonium Compounds	FGF2 SNP affects the susceptibility to Benzalkonium Compounds	27206134
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased susceptibility to FGF2 protein	20876236
D001564	Benzo(a)pyrene	alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	20876236
D001564	Benzo(a)pyrene	alpha-naphthoflavone inhibits the reaction [Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the methylation of FGF2 intron	30157460
D001564	Benzo(a)pyrene	Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased expression of ITGAV protein]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased expression of [ITGAV protein binds to ITGB3 protein]]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased expression of ITGB3 protein]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	20876236
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of FGF2 mRNA	19181443
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
C070515	bisindolylmaleimide I	bisindolylmaleimide I promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]	11742803
C006780	bisphenol A	bisphenol A results in increased expression of FGF2 mRNA	30248606
C006780	bisphenol A	bisphenol A results in decreased expression of FGF2 mRNA	27022677
C006780	bisphenol A	bisphenol A results in decreased expression of FGF2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of FGF2 gene	28505145
D001761	Bleomycin	Bleomycin results in increased expression of FGF2 protein	25582705
D001761	Bleomycin	protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of FGF2 protein]	25582705
C032688	boric acid	boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D003994	Bucladesine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA	29698629
D003994	Bucladesine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA	29698629
D003994	Bucladesine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA	29698629
D003994	Bucladesine	[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA	29698629
D002101	Cacodylic Acid	Cacodylic Acid results in increased expression of FGF2 mRNA	15345372
D002104	Cadmium	Cadmium results in decreased expression of FGF2 mRNA	20570719
C058819	calphostin C	calphostin C inhibits the reaction [FGF2 protein results in increased expression of and results in increased activity of RUNX2 protein]	12403780
C058819	calphostin C	calphostin C inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
D002211	Capsaicin	Capsaicin results in decreased expression of FGF2 protein	14521749
D002251	Carbon Tetrachloride	FGF2 protein affects the susceptibility to Carbon Tetrachloride	14507672
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of FGF2 mRNA	17158861
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of FGF2 protein	16116963
D002330	Carmustine	FGF2 protein results in decreased susceptibility to Carmustine	20221717
C086276	cerivastatin	cerivastatin results in decreased expression of FGF2 mRNA	11479256
C086276	cerivastatin	cerivastatin results in decreased expression of FGF2 protein	11479256
D002713	Chlorine	Chlorine results in decreased expression of FGF2 mRNA	18636392
D002713	Chlorine	[Ozone co-treated with Chlorine] affects the expression of FGF2 mRNA	18636392
D002746	Chlorpromazine	[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of FGF2 mRNA	17589599
D002793	Cholic Acids	[1-Naphthylisothiocyanate co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
D002793	Cholic Acids	[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
D002793	Cholic Acids	[Cyclosporine co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
D002809	Chondroitin Sulfates	Chondroitin Sulfates analog binds to FGF2 protein	12221095
D002809	Chondroitin Sulfates	[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein	15385557
D002809	Chondroitin Sulfates	[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein	14699094
C000628468	ciji-hua'ai-baosheng	ciji-hua'ai-baosheng results in decreased expression of FGF2 protein	29957915
D017315	Cilazapril	Cilazapril results in decreased expression of FGF2 mRNA	9640960
D017315	Cilazapril	Cilazapril results in decreased expression of FGF2 protein	9640960
C065927	cilnidipine	cilnidipine results in decreased expression of FGF2 mRNA	16333380
D002945	Cisplatin	Cisplatin affects the reaction [Piroxicam results in decreased expression of FGF2 mRNA]	21858171
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of FGF2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of FGF2 mRNA	27392435
D003008	Cloprostenol	Cloprostenol results in increased expression of FGF2 mRNA	14991729
D003024	Clozapine	Clozapine results in increased expression of FGF2 mRNA	11264663
C000593591	coagulin-L	coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27568862
C018021	cobaltous chloride	[BAY 60-6583 co-treated with cobaltous chloride] results in increased expression of FGF2 protein	27590504
D003042	Cocaine	Cocaine results in decreased expression of FGF2 mRNA	12629581
D003078	Colchicine	Colchicine affects the expression of FGF2 protein	7714246
D005576	Colforsin	Colforsin results in increased expression of FGF2 mRNA	10320526
D005576	Colforsin	Colforsin results in increased expression of FGF2 protein	10320526
D019327	Copper Sulfate	Copper Sulfate inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	22842628
D019327	Copper Sulfate	Copper Sulfate inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	22842628
D016578	Crack Cocaine	Crack Cocaine results in increased expression of FGF2 mRNA	12629581
D003471	Cuprizone	Cuprizone results in decreased expression of FGF2 mRNA	26577399
D003471	Cuprizone	Cuprizone results in increased expression of FGF2 mRNA	27523638
D003474	Curcumin	Curcumin results in decreased expression of FGF2 protein	23555722
D003474	Curcumin	Curcumin results in increased expression of FGF2 protein	23555722
D000242	Cyclic AMP	Cyclic AMP inhibits the reaction [FGF2 results in increased activity of AKT1]	16963022
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
D003513	Cycloheximide	Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]	9798919
D016572	Cyclosporine	[Cyclosporine co-treated with Cholic Acids] affects the expression of FGF2 mRNA	27344345
D016572	Cyclosporine	Cyclosporine results in increased expression of FGF2 mRNA	27989131
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D003609	Dactinomycin	Dactinomycin results in decreased expression of FGF2 mRNA	26800359
D003609	Dactinomycin	Dactinomycin inhibits the reaction [FGF2 protein results in increased expression of SNCA protein]	12562524
D003671	DEET	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of and results in increased secretion of FGF2 protein	28659758
D003871	Dermatan Sulfate	[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein	15385557
D003871	Dermatan Sulfate	Dermatan Sulfate analog results in increased activity of FGF2 protein	15563459
D003871	Dermatan Sulfate	[Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein	14699094
D003907	Dexamethasone	Dexamethasone results in increased expression of FGF2 mRNA	26468166
D003907	Dexamethasone	boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D003907	Dexamethasone	[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein	28285642
D003907	Dexamethasone	Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27568862
D003907	Dexamethasone	sodium pentaborate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D003907	Dexamethasone	Dexamethasone inhibits the reaction [nitrofen results in decreased expression of FGF2 mRNA]	10646786
D016264	Dextran Sulfate	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA	29950665
D003975	Diazepam	Diazepam results in increased expression of FGF2 mRNA	19114084
D003976	Diazinon	Diazinon affects the expression of FGF2 mRNA	22546817
D003976	Diazinon	Diazinon results in decreased expression of FGF2 mRNA	17589599; 19130878;
D004026	Dieldrin	Dieldrin affects the expression of FGF2 mRNA	22546817
D004026	Dieldrin	Dieldrin results in decreased expression of FGF2 mRNA	19130878
D004041	Dietary Fats	Dietary Fats results in decreased expression of FGF2 mRNA	29197120
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of FGF2 protein	24632418
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of FGF2 mRNA	17005392
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of FGF2 mRNA	20421132
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of FGF2 protein	20421132
D013196	Dihydrotestosterone	Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 mRNA]	20421132
D013196	Dihydrotestosterone	Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 protein]	20421132
D015237	Dinoprost	Dinoprost affects the expression of FGF2 mRNA	20484870
D015237	Dinoprost	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
D015237	Dinoprost	Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
D015237	Dinoprost	Dinoprost affects the localization of FGF2 protein	15654655
D015237	Dinoprost	Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]	16365892
D015237	Dinoprost	Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]	16365892
D015237	Dinoprost	Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
C493087	diphenylarsinic acid	diphenylarsinic acid results in increased secretion of FGF2 protein	26645585; 28087833;
C493087	diphenylarsinic acid	pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C493087	diphenylarsinic acid	SB 203580 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C493087	diphenylarsinic acid	SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C493087	diphenylarsinic acid	U 0126 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C007517	diphenyleneiodonium	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Nitric Oxide]	19539746
C007517	diphenyleneiodonium	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Reactive Oxygen Species]	19539746
D016291	Dizocilpine Maleate	Dizocilpine Maleate results in increased expression of FGF2 mRNA	9832142
D004280	Dobutamine	FGF2 protein affects the susceptibility to Dobutamine	14583313
D004280	Dobutamine	FGF2 protein affects the susceptibility to Dobutamine	10491406
D000077143	Docetaxel	[O-(Chloroacetylcarbamoyl)fumagillol co-treated with Docetaxel] results in decreased expression of FGF2 protein	12576464
C516138	dorsomorphin	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF2 mRNA	27188386
D004317	Doxorubicin	Doxorubicin results in decreased expression of FGF2 mRNA	29803840
D004365	Drugs, Chinese Herbal	Drugs, Chinese Herbal inhibits the reaction [FGF2 protein results in increased phosphorylation of FGFR1 protein]	25856345
D004365	Drugs, Chinese Herbal	Drugs, Chinese Herbal results in increased expression of FGF2 mRNA	16313111; 17717918;
C117757	E 5842	E 5842 results in decreased expression of FGF2 mRNA	11264663
C117757	E 5842	E 5842 results in increased expression of FGF2 mRNA	11264663
C117757	E 5842	E 5842 results in increased expression of FGF2 protein	11264663
C118739	entinostat	entinostat results in increased expression of FGF2 mRNA	26272509
C118739	entinostat	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF2 mRNA	27188386
C045651	epigallocatechin gallate	epigallocatechin gallate results in decreased expression of FGF2 mRNA	16084531
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA	22079256
D004958	Estradiol	Estradiol results in increased expression of FGF2 mRNA	15367264
D004958	Estradiol	[Estradiol binds to ESR2 protein] which results in decreased expression of FGF2 mRNA	20404318
D004958	Estradiol	Estradiol results in increased expression of FGF2 mRNA	21098263
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in increased expression of FGF2 mRNA	18692832
C024552	estrone benzoate	estrone benzoate results in decreased expression of FGF2 mRNA	15120423
C024552	estrone benzoate	Progesterone inhibits the reaction [estrone benzoate results in decreased expression of FGF2 mRNA]	15120423
D000431	Ethanol	Ethanol results in decreased expression of FGF2 mRNA	26177723
D000431	Ethanol	Ethanol results in increased expression of FGF2 mRNA	28789864
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of FGF2 mRNA	23550701
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate analog inhibits the reaction [FGF2 protein results in increased phosphorylation of FGFR1 protein]	21517068
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate analog promotes the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	21517068
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate inhibits the reaction [FGF2 protein results in increased phosphorylation of FGFR1 protein]	21517068
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	21517068
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	21517068
C560274	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate	ethyl 8-oxo-8H-acenaphtho(1,2-b)pyrrole-9-carboxylate promotes the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	21517068
D005047	Etoposide	FGF2 protein affects the susceptibility to Etoposide	16217747
D015738	Famotidine	[Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA	17717918
C545733	fatostatin	fatostatin results in decreased expression of FGF2 mRNA	19716478
D018818	Fenoldopam	Fenoldopam results in increased expression of FGF2 protein	12180796
D017313	Fenretinide	Fenretinide results in decreased expression of FGF2 mRNA	28973697
D018120	Finasteride	Finasteride inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF2 mRNA	28329830
D005472	Fluorouracil	Fluorouracil results in decreased expression of FGF2 mRNA	16510598
D005473	Fluoxetine	[Fluoxetine co-treated with Olanzapine] results in increased expression of FGF2 mRNA	15158429
D005485	Flutamide	Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 mRNA]	20421132
D005485	Flutamide	Flutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FGF2 protein]	20421132
D005485	Flutamide	Flutamide results in increased expression of FGF2 mRNA	24793618
D000068759	Formoterol Fumarate	[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]	18076728
D000068759	Formoterol Fumarate	Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]	18076728
D000068759	Formoterol Fumarate	Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]	18076728
D000068759	Formoterol Fumarate	Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]	18076728
C442779	fruit extract, Alpinia oxyphylla	fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of FGF2 protein]	30367734
C069837	fullerene C60	fullerene C60 results in decreased expression of FGF2 mRNA	19167457
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [FGF2 protein results in increased expression of CCND1 protein]	20179196
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA]	23596885
C039281	furan	furan results in decreased methylation of FGF2 gene	27387713
C039281	furan	furan results in increased expression of FGF2 mRNA	27387713
D005665	Furosemide	Furosemide results in decreased expression of FGF2 mRNA	16526316
D005690	Galactose	fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of FGF2 protein]	30367734
D005690	Galactose	Galactose results in increased expression of FGF2 protein	30367734
D000077156	Gefitinib	Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein]	19885553
C056507	gemcitabine	[gemcitabine co-treated with IFNA2 protein] results in increased expression of FGF2 protein	12738744
C056507	gemcitabine	gemcitabine results in increased expression of FGF2 protein	20531411
D019833	Genistein	Genistein results in decreased activity of FGF2 protein	10569980
D019833	Genistein	[Genistein co-treated with Methoxychlor] results in decreased expression of FGF2 mRNA	21782745
D005944	Glucosamine	Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA]	1518840
D005947	Glucose	Glucosamine promotes the reaction [Glucose results in increased expression of FGF2 mRNA]	1518840
D005947	Glucose	Glucose results in increased expression of FGF2 mRNA	1518840
D005947	Glucose	Glucose results in increased expression of FGF2 protein	19759273
D006025	Glycosaminoglycans	Glycosaminoglycans results in increased activity of FGF2 protein	12659634
D006072	Gossypol	Gossypol results in decreased expression of FGF2 mRNA	19825521
D006072	Gossypol	Zoledronic Acid promotes the reaction [Gossypol results in decreased expression of FGF2 mRNA]	19825521
D019812	Heparan Sulfate Proteoglycans	[Heparan Sulfate Proteoglycans binds to and results in increased activity of FGF2 protein] which results in increased expression of TNFSF11 protein	15334457
D019812	Heparan Sulfate Proteoglycans	[Heparan Sulfate Proteoglycans binds to FGF2 protein binds to FGFR1 protein] which binds to ANOS1 protein	15548653
D019812	Heparan Sulfate Proteoglycans	Heparan Sulfate Proteoglycans affects the reaction [FGF2 protein binds to FGFR1 protein]	10336501
D019812	Heparan Sulfate Proteoglycans	Heparan Sulfate Proteoglycans affects the reaction [FGF2 protein binds to FGFR4 protein]	10336501
D019812	Heparan Sulfate Proteoglycans	Heparan Sulfate Proteoglycans binds to FGF2 protein	8227197
D006493	Heparin	Heparin promotes the reaction [FGF2 protein binds to FGFR1 protein]	12440867
D006493	Heparin	Heparin results in decreased activity of FGF2 protein	10569980; 15051888;
D006493	Heparin	Heparin binds to FGF2 protein	17524524
D006493	Heparin	Heparin binds to FGFR1 protein binds to FGF2 protein	15096041
D006493	Heparin	Heparin promotes the reaction [FGFR1 protein binds to FGF2 protein]	1379594
D006493	Heparin	Heparin promotes the reaction [FGFR2 protein binds to FGF2 protein]	1373495
D006493	Heparin	Heparin affects the activity of FGF2 protein	15232299
D006493	Heparin	Heparin affects the reaction [FGF2 protein binds to FGFR4 protein]	10336501
D006493	Heparin	[Heparin binds to FGFR2 protein alternative form] which binds to FGF2 protein	10860838
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	14966081
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]	14966081
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein]	14966081
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	14966081
D006493	Heparin	Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	14966081
D006493	Heparin	Heparin results in decreased expression of FGF2 protein	8441232
D006493	Heparin	Heparin analog binds to and results in decreased degradation of FGF2 protein	9174673
D006493	Heparin	Heparin binds to FGF2 protein	15632177; 7547864;
D006493	Heparin	Heparin promotes the reaction [FGF2 protein results in increased activity of FGFR1 protein]	12799194
D006493	Heparin	Heparin results in increased activity of FGF2 protein	12799194
D006493	Heparin	phosphomannopentaose sulfate inhibits the reaction [Heparin binds to FGF2 protein]	15632177
D006497	Heparitin Sulfate	Heparitin Sulfate binds to and affects the activity of FGF2 protein	15958608
D006497	Heparitin Sulfate	Heparitin Sulfate analog results in increased activity of FGF2 protein	12460940
D006497	Heparitin Sulfate	Heparitin Sulfate binds to FGF2 protein	15464572
D006497	Heparitin Sulfate	Heparitin Sulfate analog binds to FGF2 protein	14707131; 15081013;
D006583	Hexadimethrine Bromide	Hexadimethrine Bromide results in decreased activity of FGF2 protein	10569980
D006583	Hexadimethrine Bromide	Hexadimethrine Bromide results in decreased susceptibility to FGF2 protein	21887340
C482862	heyneanol A	heyneanol A results in decreased activity of FGF2 protein	16675471
D006851	Hydrochloric Acid	Hydrochloric Acid results in decreased expression of FGF2 mRNA	15046208
D006861	Hydrogen Peroxide	Hydrogen Peroxide promotes the reaction [FGF2 protein binds to FGFR1 protein]	8849686
D006861	Hydrogen Peroxide	Hydrogen Peroxide inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	22842628
D006861	Hydrogen Peroxide	Hydrogen Peroxide inhibits the reaction [SLC31A1 gene mutant form inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	22842628
C005044	hydroxyethyl methacrylate	Acetylcysteine inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]	19176594
C005044	hydroxyethyl methacrylate	hydroxyethyl methacrylate results in increased secretion of FGF2 protein	19176594
C005044	hydroxyethyl methacrylate	pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]	19176594
D016285	Iloprost	Iloprost results in increased expression of FGF2 mRNA	16373414
D016285	Iloprost	RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA]	16373414
D000077271	Imiquimod	Imiquimod results in decreased expression of FGF2	16368197
D000077271	Imiquimod	Imiquimod results in decreased expression of FGF2	16302556
C016517	indole-3-carbinol	indole-3-carbinol affects the expression of FGF2 mRNA	21396975
D007213	Indomethacin	Indomethacin inhibits the reaction [FGF2 protein results in increased expression of CCND1 protein]	11170841
D007213	Indomethacin	Indomethacin inhibits the reaction [FGF2 protein results in increased expression of CCNE1 protein]	11170841
D007213	Indomethacin	Indomethacin inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein]	11170841
D007213	Indomethacin	Indomethacin results in increased expression of FGF2 mRNA	17440234
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FGF2 mRNA	25613284
D000077146	Irinotecan	Irinotecan metabolite results in increased expression of FGF2 mRNA	15956246
D000077146	Irinotecan	Irinotecan results in increased expression of FGF2 mRNA	15956246
D017275	Isradipine	Isradipine results in increased secretion of FGF2 protein	15257873
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of FGF2 mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of FGF2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of FGF2 mRNA	25961927
D007608	Kainic Acid	Kainic Acid results in increased expression of FGF2 mRNA	7649223
D064747	Lansoprazole	Lansoprazole results in decreased expression of FGF2 protein	9881512
C005136	lasiocarpine	lasiocarpine metabolite results in decreased expression of FGF2 mRNA	30465738
C008261	lead acetate	lead acetate results in decreased expression of FGF2 mRNA	22160880
D000077339	Leflunomide	Leflunomide results in increased expression of FGF2 mRNA	19751817
D007975	Leukotriene B4	Leukotriene B4 results in increased expression of FGF2 mRNA	30818366
C482199	lipopolysaccharide, E coli O55-B5	lipopolysaccharide, E coli O55-B5 results in increased secretion of FGF2 protein	24073415
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased secretion of FGF2 protein	24431307
D008070	Lipopolysaccharides	valdecoxib affects the reaction [Lipopolysaccharides results in increased secretion of FGF2 protein]	24431307
D008070	Lipopolysaccharides	coagulin-L inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27568862
D008070	Lipopolysaccharides	Dexamethasone inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27568862
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of FGF2 protein	27568862
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of FGF2 protein	27098997; 30980805;
D008070	Lipopolysaccharides	Plant Extracts inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27098997
D008070	Lipopolysaccharides	U 0126 inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	30980805
D047311	Luteolin	Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
C025340	manganese chloride	manganese chloride results in decreased expression of FGF2 mRNA	28801915
C025340	manganese chloride	manganese chloride results in increased methylation of FGF2 gene	28801915
D008464	Mecamylamine	Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]	9832142
D008555	Melitten	Melitten results in decreased expression of FGF2 mRNA	18076793
D000077239	Meloxicam	Meloxicam inhibits the reaction [IFNE protein results in increased expression of FGF2 mRNA]	21270428
D008628	Mercury	Mercury results in increased expression of FGF2 mRNA	16823088
D008694	Methamphetamine	Methamphetamine results in increased expression of FGF2 mRNA	19564919
D008731	Methoxychlor	[Genistein co-treated with Methoxychlor] results in decreased expression of FGF2 mRNA	21782745
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of FGF2 mRNA	23103053
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of FGF2 mRNA	23179753; 28001369;
D008767	Methylmercury Compounds	Methylmercury Compounds results in decreased expression of FGF2 mRNA	19652467
D008767	Methylmercury Compounds	Methylmercury Compounds results in decreased expression of FGF2 protein	19652467
C008493	methylselenic acid	methylselenic acid results in decreased expression of FGF2 mRNA	12517777
D016685	Mitomycin	Mitomycin results in increased expression of FGF2 protein	16585851
C020300	monomethylarsonic acid	monomethylarsonic acid results in increased expression of FGF2 mRNA	15345372
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of FGF2 mRNA	22108045
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of FGF2 protein	24625837
D009020	Morphine	Morphine results in decreased secretion of FGF2 protein	20564181
D009020	Morphine	Naloxone inhibits the reaction [Morphine results in decreased secretion of FGF2 protein]	20564181
D009020	Morphine	OPRM1 protein affects the reaction [Morphine results in decreased secretion of FGF2 protein]	20564181
D009151	Mustard Gas	Mustard Gas results in increased expression of FGF2 mRNA	27617619
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FGF2 protein results in increased expression of BDNF mRNA]	16269011
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FGF2 protein results in increased expression of NTRK2 mRNA]	16269011
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FGF2 protein results in increased phosphorylation of CREB1 protein]	16269011
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	16269011
D009270	Naloxone	Naloxone inhibits the reaction [Morphine results in decreased secretion of FGF2 protein]	20564181
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of FGF2 mRNA	25554681
C005274	naringin	Fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA]	23596885
C005274	naringin	naringin results in increased expression of FGF2 mRNA	23596885
D009532	Nickel	Nickel results in decreased expression of FGF2 mRNA	19130878
C022838	nickel chloride	nickel chloride affects the expression of FGF2 mRNA	22546817
C028007	nickel monoxide	nickel monoxide results in decreased expression of FGF2 mRNA	19167457
C029938	nickel sulfate	nickel sulfate results in increased expression of FGF2 mRNA	22714537
D009538	Nicotine	EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]	22198237
D009538	Nicotine	Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]	22198237
D009538	Nicotine	Nicotine results in increased secretion of FGF2 protein	16365874; 22198237;
D009538	Nicotine	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]	22198237
D009538	Nicotine	[triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA	22198237; 22198237;
D009538	Nicotine	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]	22198237
D009538	Nicotine	Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]	9832142
D009538	Nicotine	Nicotine results in decreased expression of FGF2 protein	14732461
D009538	Nicotine	Nicotine results in increased expression of FGF2 mRNA	15465631; 18190895; 22198237; 9503263; 9832142;
D009538	Nicotine	Nicotine results in increased expression of FGF2 protein	15465631; 18190895;
D009538	Nicotine	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]	22198237
D009538	Nicotine	Nicotine results in increased secretion of FGF2 protein	17630920
D009543	Nifedipine	Nifedipine affects the susceptibility to FGF2 protein	15141722
D009543	Nifedipine	Nifedipine inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA]	16188231
D009569	Nitric Oxide	[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Nitric Oxide	19539746
D009569	Nitric Oxide	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Nitric Oxide]	19539746
C007350	nitrofen	Dexamethasone inhibits the reaction [nitrofen results in decreased expression of FGF2 mRNA]	10646786
C007350	nitrofen	nitrofen results in decreased expression of FGF2 mRNA	10646786; 10898222;
D009599	Nitroprusside	FGF2 protein results in decreased susceptibility to Nitroprusside	10203697
D009599	Nitroprusside	FGF2 protein inhibits the reaction [Nitroprusside results in decreased expression of BCL2 protein]	10203697
D009599	Nitroprusside	FGF2 protein inhibits the reaction [Nitroprusside results in increased expression of BAX protein]	10203697
D009638	Norepinephrine	[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]	11742803
D000077609	O-(Chloroacetylcarbamoyl)fumagillol	[O-(Chloroacetylcarbamoyl)fumagillol co-treated with Docetaxel] results in decreased expression of FGF2 protein	12576464
D000077609	O-(Chloroacetylcarbamoyl)fumagillol	O-(Chloroacetylcarbamoyl)fumagillol results in decreased expression of FGF2 protein	12576464
D000077152	Olanzapine	[Fluoxetine co-treated with Olanzapine] results in increased expression of FGF2 mRNA	15158429
D009844	Oligosaccharides	Oligosaccharides binds to and results in decreased degradation of FGF2 protein	9174673
C000594117	ON123300	ON123300 inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	24568969
C000594117	ON123300	ON123300 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	24568969
C000594117	ON123300	ON123300 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	24568969
D010069	Oxadiazoles	AHR mutant form inhibits the reaction [[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA]	23212921
D010069	Oxadiazoles	ARNT mutant form inhibits the reaction [[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA]	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of ALKAL2 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of CSN1S1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of CSN3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of DCPP1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of GDAP1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of GPR34 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of KRTAP17-1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of LAO1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of LUZP2 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of MLIP mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of NTRK2 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of SLC35D3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in decreased expression of SLITRK1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of ADH7 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of AHRR mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of ALDH3A1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of AQP3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of C1QTNF3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of CES1F mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of CWH43 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of CYP1A1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of CYP1B1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DEFB1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSC1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSG3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of DSG3 protein	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of ENDOU mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of GJB6 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of GSTA1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of GSTA3 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of IL1F9 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of MAL mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of MSLNL mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of MSLN mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of NQO1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of PTGS1 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of SERPINB3B mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of SLC7A11 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of SNHG11 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of SPINK12 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of STFA2 mRNA	23212921
D010069	Oxadiazoles	[Oxadiazoles analog co-treated with FGF2 protein] results in increased expression of UGT1A6B mRNA	23212921
C012466	oxadiazon	ACYP2 protein affects the reaction [oxadiazon inhibits the reaction [FGF2 protein results in increased expression of GAP43 protein]]	30391265
C012466	oxadiazon	oxadiazon inhibits the reaction [FGF2 protein results in increased expression of GAP43 protein]	30391265
C026055	oxilofrine	oxilofrine inhibits the reaction [VEGFA protein results in increased expression of FGF2 protein]	20643105
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of FGF2 mRNA	30529165
D010100	Oxygen	Oxygen inhibits the reaction [Paraquat results in increased expression of FGF2 mRNA]	26722498
D010126	Ozone	[Ozone co-treated with Chlorine] affects the expression of FGF2 mRNA	18636392
D017239	Paclitaxel	FGF2 protein results in decreased susceptibility to Paclitaxel	16741658
D010269	Paraquat	Paraquat results in decreased secretion of FGF2 protein	30698896
D010269	Paraquat	Oxygen inhibits the reaction [Paraquat results in increased expression of FGF2 mRNA]	26722498
D010269	Paraquat	Paraquat results in increased expression of FGF2 mRNA	18198484; 26722498;
C002669	parthenolide	parthenolide inhibits the reaction [FGF2 protein results in increased activity of [NFKB1 protein binds to RELA protein]]	16921510
C002669	parthenolide	parthenolide inhibits the reaction [FGF2 protein results in increased expression of TRAF1 mRNA]	16921510
C002669	parthenolide	parthenolide inhibits the reaction [FGF2 protein results in increased expression of TRAF2 mRNA]	16921510
D052638	Particulate Matter	Particulate Matter results in increased expression of FGF2 mRNA	24769257
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of FGF2 mRNA	18593933
C109647	PD 166285	PD 166285 inhibits the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of AKT1 protein]	25426952
C109647	PD 166285	PD 166285 inhibits the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]	25426952
C109647	PD 166285	PD 166285 inhibits the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]	25426952
C109647	PD 166285	PD 166285 results in decreased activity of FGF2 protein	25426952
C101814	perfluoro-n-undecanoic acid	perfluoro-n-undecanoic acid results in increased expression of FGF2 mRNA	23602845
D026023	Permethrin	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of and results in increased secretion of FGF2 protein	28659758
D010656	Phenylephrine	Phenylephrine promotes the reaction [EGR1 protein binds to FGF2 promoter]	10779383
C120158	phosphomannopentaose sulfate	phosphomannopentaose sulfate analog binds to FGF2 protein	16366604
C120158	phosphomannopentaose sulfate	phosphomannopentaose sulfate binds to FGF2 protein	16366604
C120158	phosphomannopentaose sulfate	phosphomannopentaose sulfate inhibits the reaction [Heparin binds to FGF2 protein]	15632177
D010862	Pilocarpine	FGF2 inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]	21087489
D010894	Piroxicam	Cisplatin affects the reaction [Piroxicam results in decreased expression of FGF2 mRNA]	21858171
D010894	Piroxicam	Piroxicam results in decreased expression of FGF2 mRNA	21858171
D010936	Plant Extracts	Plant Extracts results in decreased expression of FGF2 mRNA	23232078
D010936	Plant Extracts	Plant Extracts inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	27098997
C108953	platycodin D	platycodin D results in decreased expression of FGF2 protein	29595072
D059808	Polyphenols	Polyphenols results in decreased expression of FGF2 mRNA	16293270
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of FGF2 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of FGF2 mRNA	22079256
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of FGF2 protein	23718831
D011374	Progesterone	FGF2 protein results in increased abundance of Progesterone	18213648
D011374	Progesterone	Progesterone results in increased expression of FGF2 mRNA	23018184
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in increased expression of FGF2 mRNA	18692832
D011374	Progesterone	Progesterone inhibits the reaction [estrone benzoate results in decreased expression of FGF2 mRNA]	15120423
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of FGF2 mRNA	24780913
C005581	protocatechualdehyde	protocatechualdehyde inhibits the reaction [TGFB1 protein results in increased expression of FGF2 protein]	25582705
C005581	protocatechualdehyde	protocatechualdehyde inhibits the reaction [Bleomycin results in increased expression of FGF2 protein]	25582705
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]	19176594
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of FGF2 mRNA]	12832416
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]	25290095
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
D011729	Pyridostigmine Bromide	[Pyridostigmine Bromide co-treated with DEET co-treated with Permethrin] results in increased expression of and results in increased secretion of FGF2 protein	28659758
C587274	Qing Ye Dan	Qing Ye Dan inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
D011794	Quercetin	Quercetin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D017382	Reactive Oxygen Species	[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Reactive Oxygen Species	19539746
D017382	Reactive Oxygen Species	diphenyleneiodonium inhibits the reaction [[6,8-dichloro-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine co-treated with FGF2 protein] results in increased abundance of Reactive Oxygen Species]	19539746
D000077185	Resveratrol	Resveratrol results in decreased expression of FGF2 mRNA	17935668
D000077185	Resveratrol	Resveratrol results in decreased expression of FGF2 protein	17935668; 20028382;
D000077185	Resveratrol	Resveratrol inhibits the reaction [FGF2 protein results in increased expression of TNFRSF11B mRNA]	25290095
D000077185	Resveratrol	Resveratrol inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	25290095
D000077185	Resveratrol	Resveratrol inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]	25290095
D000077185	Resveratrol	Resveratrol results in decreased activity of FGF2 protein	16675471
D000077185	Resveratrol	Resveratrol results in decreased expression of FGF2 mRNA	25338179
D012402	Rotenone	Rotenone results in decreased expression of FGF2 mRNA	29955902
C085746	rottlerin	rottlerin inhibits the reaction [FGF2 protein results in increased activity of RUNX2 protein]	12403780
C085746	rottlerin	rottlerin inhibits the reaction [FGF2 protein results in increased expression of RUNX2 mRNA]	12403780
C101044	RTKI cpd	RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA]	16373414
C079198	S 1 (combination)	S 1 (combination) results in decreased expression of FGF2 mRNA	18607998
C025759	saikosaponin	saikosaponin results in decreased expression of FGF2 protein	29129800
C093642	SB 203580	SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]	15631803
C093642	SB 203580	SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein]	15249425
C093642	SB 203580	SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
C093642	SB 203580	SB 203580 results in decreased activity of FGF2 protein	15249425
C093642	SB 203580	SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]	25290095
C093642	SB 203580	SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]	21108934
C093642	SB 203580	SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]	21108934
C093642	SB 203580	SB 203580 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C093642	SB 203580	SB 203580 results in increased secretion of FGF2 protein	28087833
C587178	SCH772984	SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
C587178	SCH772984	SCH772984 results in increased secretion of FGF2 protein	28087833
C484876	scutellarin	scutellarin results in decreased expression of FGF2 protein	16297343
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of FGF2 mRNA	25351596
D012822	Silicon Dioxide	Silicon Dioxide results in increased secretion of FGF2 protein	22300531; 25351596;
D012834	Silver	Silver results in increased expression of FGF2 mRNA	26551752
D000077385	Silybin	Silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein]	16788158
D019821	Simvastatin	Simvastatin results in increased expression of FGF2	20381859
D012906	Smoke	Smoke results in decreased nitrosation of FGF2 protein	21652289
D012906	Smoke	Smoke results in increased expression of FGF2 mRNA	21095227
D026423	S-Nitroso-N-Acetylpenicillamine	S-Nitroso-N-Acetylpenicillamine promotes the reaction [FGF2 protein results in increased expression of TP53 protein]	16351512
C017947	sodium arsenite	sodium arsenite results in decreased expression of FGF2 mRNA	19615344
C017947	sodium arsenite	sodium arsenite results in increased expression of FGF2 mRNA	12703962
C017947	sodium arsenite	sodium arsenite results in increased expression of FGF2 mRNA	28370166
D012965	Sodium Chloride	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Sodium Chloride results in increased secretion of FGF2 protein]	26800359
D012965	Sodium Chloride	Apigenin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	Dactinomycin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	Luteolin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	NFAT5 protein affects the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	NFAT5 protein affects the reaction [Sodium Chloride results in increased secretion of FGF2 protein]	26800359
D012965	Sodium Chloride	pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	Quercetin inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA]	26800359
D012965	Sodium Chloride	Sodium Chloride results in increased expression of FGF2 mRNA	26800359
D012965	Sodium Chloride	Sodium Chloride results in increased secretion of FGF2 protein	26800359
C538809	sodium pentaborate	sodium pentaborate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]	28285642
D012999	Soman	Soman results in increased expression of FGF2 mRNA	19281266
D013148	Spironolactone	Spironolactone results in decreased activity of FGF2 protein	8921802
C525422	SRT1720	SRT1720 inhibits the reaction [FGF2 protein results in increased expression of TNFRSF11B mRNA]	25290095
C525422	SRT1720	SRT1720 inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	25290095
C525422	SRT1720	SRT1720 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]	25290095
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased expression of and results in increased activity of HIF1A protein]	15631803
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA]	16188231
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased expression of TACR1 mRNA alternative form]	16154193
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]	15631803
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]	15631803
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	15631803
C105686	SU 5402	SU 5402 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	15631803
C105686	SU 5402	SU 5402 results in decreased expression of FGF2 mRNA	12421715
C105686	SU 5402	SU 5402 results in increased expression of FGF2 mRNA	12421715
C105686	SU 5402	SU 5402 results in decreased activity of FGF2 protein	12076337
D013392	Sucralfate	[Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA	17717918
D013395	Sucrose	Sucrose results in increased expression of FGF2 mRNA	26800359
D013498	Suramin	Suramin results in increased expression of FGF2	8394679
C013270	swertiamarin	swertiamarin inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
D013629	Tamoxifen	FGF2 protein results in decreased susceptibility to Tamoxifen	20179196
D013629	Tamoxifen	Tamoxifen inhibits the reaction [FGF2 protein results in increased expression of CCND1 protein]	20179196
D000077204	Temozolomide	[Temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein	16327979
D013713	Teniposide	FGF2 protein results in decreased susceptibility to Teniposide	20221717
D013739	Testosterone	Finasteride inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
D013739	Testosterone	Qing Ye Dan inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
D013739	Testosterone	swertiamarin inhibits the reaction [Testosterone results in increased expression of FGF2 protein]	27866977
D013739	Testosterone	Testosterone results in increased expression of FGF2 protein	27866977
D013749	Tetrachlorodibenzodioxin	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FGF2 mRNA]	23625689
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FGF2 mRNA	12377990; 23625689; 30096437;
D013749	Tetrachlorodibenzodioxin	AHR mutant form inhibits the reaction [[Tetrachlorodibenzodioxin analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA]	23212921
D013749	Tetrachlorodibenzodioxin	ARNT mutant form inhibits the reaction [[Tetrachlorodibenzodioxin analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA]	23212921
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of FGF2 mRNA	12167310
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin analog co-treated with FGF2 protein] results in increased expression of DSG1A mRNA	23212921
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with FGF2 protein] results in increased expression of DSC1 mRNA	23212921
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with FGF2 protein] results in increased expression of DSG3 mRNA	23212921
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with FGF2 protein] results in increased expression of DSG3 protein	23212921
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased activity of FGF2 protein	20486776; 23212921;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of FGF2 mRNA	21724226
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased secretion of FGF2 protein	11874475
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FGF2 mRNA	25613284
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein]	15654655
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate promotes the reaction [EGR1 protein binds to FGF2 promoter]	10779383
C020809	tetrathiomolybdate	[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	18480265
C020809	tetrathiomolybdate	[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	18480265
C020809	tetrathiomolybdate	Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	18480265
C020809	tetrathiomolybdate	Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	18480265
C020809	tetrathiomolybdate	Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	18480265
C020809	tetrathiomolybdate	Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	18480265
D013792	Thalidomide	Thalidomide results in decreased expression of FGF2 mRNA	30834740
D013792	Thalidomide	FGF2 protein results in increased susceptibility to Thalidomide	11555579
D013792	Thalidomide	Thalidomide affects the expression of FGF2 mRNA	15939924
D013792	Thalidomide	Thalidomide affects the expression of FGF2 protein	15939924
D013792	Thalidomide	Thalidomide affects the secretion of FGF2 protein	15939924
D013792	Thalidomide	Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein]	14558594
D013792	Thalidomide	Thalidomide results in decreased activity of FGF2 protein	17557286
D013792	Thalidomide	Thalidomide results in decreased expression of FGF2 protein	12644816; 15863203;
D013792	Thalidomide	[Temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein	16327979
D013974	Thyroxine	Thyroxine results in increased expression of FGF2 mRNA	23935926
C016151	tinuvin	tinuvin analog results in decreased expression of FGF2 mRNA	30315675
C009495	titanium dioxide	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA	29950665
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF2 protein	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF2 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of FGF2 protein	27793746
D024505	Tocopherols	Tocopherols results in decreased expression of FGF2 mRNA	15878867
D019772	Topotecan	FGF2 protein affects the susceptibility to Topotecan	16217747
D014107	Tosyllysine Chloromethyl Ketone	Tosyllysine Chloromethyl Ketone inhibits the reaction [FGF2 protein results in increased expression of NRP1 mRNA]	16289960
D014118	Toxins, Biological	Toxins, Biological affects the expression of FGF2 mRNA	19682533
C495469	trans-3-(4'-hydroxyphenyl)-2-propenoic acid	trans-3-(4'-hydroxyphenyl)-2-propenoic acid inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of FGF2 protein]	29879413
D014212	Tretinoin	Tretinoin results in decreased expression of FGF2 mRNA	21934132
D014212	Tretinoin	FGF2 protein promotes the reaction [Tretinoin results in increased expression of GAB2 protein]	16009726
D014212	Tretinoin	FGF2 protein promotes the reaction [Tretinoin results in increased expression of TUBB3 protein]	16009726
D014212	Tretinoin	FGF2 protein results in decreased susceptibility to Tretinoin	16009726
D014212	Tretinoin	GAB2 protein promotes the reaction [FGF2 protein results in decreased susceptibility to Tretinoin]	16009726
D014212	Tretinoin	Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CCND3 mRNA]	11675954
D014212	Tretinoin	Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CCNE1 mRNA]	11675954
D014212	Tretinoin	Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CDK2 mRNA]	11675954
D014212	Tretinoin	Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CDK4 mRNA]	11675954
D014212	Tretinoin	Tretinoin inhibits the reaction [FGF2 protein results in increased expression of CDK6 mRNA]	11675954
D014212	Tretinoin	Tretinoin results in decreased expression of FGF2 mRNA	20488242
D014212	Tretinoin	Tretinoin results in decreased susceptibility to FGF2 protein	11675954
C012589	trichostatin A	trichostatin A results in decreased expression of FGF2 mRNA	24935251
C012589	trichostatin A	trichostatin A results in increased expression of FGF2 mRNA	23463510
C118602	triethyl-(beta-4-stilbenoxyethyl)ammonium	EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]	22198237
C118602	triethyl-(beta-4-stilbenoxyethyl)ammonium	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]	22198237
C118602	triethyl-(beta-4-stilbenoxyethyl)ammonium	[triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA	22198237; 22198237;
C118602	triethyl-(beta-4-stilbenoxyethyl)ammonium	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]	22198237
C118602	triethyl-(beta-4-stilbenoxyethyl)ammonium	triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]	22198237
D014269	Trifluoroacetic Acid	Acrylamide analog inhibits the reaction [Trifluoroacetic Acid results in increased degradation of FGF2 protein]	14733594
D014284	Triiodothyronine	Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]	16150908
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]	16150908
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]	16150908
D014284	Triiodothyronine	[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]	11742803
D014284	Triiodothyronine	AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]	11742803
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]	12805413
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]	11742803
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]	12805413
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]	12805413
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of FGF2 mRNA	26552522
D000077288	Troglitazone	Troglitazone inhibits the reaction [FGF2 protein results in increased activity of ELK1 protein]	8878442
D000077288	Troglitazone	Troglitazone inhibits the reaction [FGF2 protein results in increased expression of FOS mRNA]	8878442
D000077288	Troglitazone	Troglitazone results in decreased susceptibility to FGF2 protein	10678274; 8878442;
C113580	U 0126	U 0126 inhibits the reaction [FGF2 protein results in increased expression of NRP1 mRNA]	16289960
C113580	U 0126	U 0126 inhibits the reaction [FGF2 protein results in increased expression of BDNF mRNA]	16269011
C113580	U 0126	U 0126 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]	21108934
C113580	U 0126	U 0126 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]	21108934
C113580	U 0126	U 0126 inhibits the reaction [Lipopolysaccharides results in increased expression of FGF2 protein]	30980805
C113580	U 0126	U 0126 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]	28087833
D014520	Urethane	Silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein]	16788158
D014520	Urethane	Urethane results in increased secretion of FGF2 protein	16788158
C406224	valdecoxib	valdecoxib affects the reaction [Lipopolysaccharides results in increased secretion of FGF2 protein]	24431307
C406224	valdecoxib	valdecoxib affects the secretion of FGF2 protein	24431307
D014635	Valproic Acid	Valproic Acid affects the expression of FGF2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of FGF2 mRNA	23179753; 24935251; 28001369;
D014635	Valproic Acid	Valproic Acid results in increased expression of FGF2 mRNA	28693025
D014635	Valproic Acid	Valproic Acid results in increased expression of FGF2 protein	28693025
D014638	Vanadates	Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	18480265
D014638	Vanadates	Vanadates inhibits the reaction [tetrathiomolybdate inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	18480265
D014638	Vanadates	Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]]	18480265
D014638	Vanadates	Vanadates inhibits the reaction [[tetrathiomolybdate results in decreased activity of SOD1 protein] inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]]	18480265
C066075	vanadium pentoxide	vanadium pentoxide results in decreased expression of FGF2 mRNA	17459161
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of FGF2 gene	25560391
D014810	Vitamin E	Vitamin E promotes the reaction [alliin results in decreased activity of FGF2 protein]	16351512
D014867	Water	Water results in increased expression of FGF2 mRNA	26800359
D000077191	Wortmannin	Wortmannin inhibits the reaction [[FGF2 protein binds to and results in increased activity of FGFR4 protein] which results in increased phosphorylation of MAPK1 protein]	11336793
C528128	xiongshao	xiongshao results in increased expression of FGF2 mRNA	22057413
C528128	xiongshao	xiongshao results in increased expression of FGF2 protein	22057413
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of FGF2 mRNA	18593933
D000077211	Zoledronic Acid	Zoledronic Acid promotes the reaction [Gossypol results in decreased expression of FGF2 mRNA]	19825521
D000077211	Zoledronic Acid	Zoledronic Acid results in decreased expression of FGF2 mRNA	24714768

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0024	Alternative initiation
KW-0037	Angiogenesis
KW-0217	Developmental protein
KW-0221	Differentiation
KW-0903	Direct protein sequencing
KW-0339	Growth factor
KW-0358	Heparin-binding
KW-1017	Isopeptide bond
KW-0488	Methylation
KW-0497	Mitogen
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0964	Secreted
KW-0832	Ubl conjugation

Interpro

InterPro ID	InterPro Term
IPR028223	FGF2
IPR002209	Fibroblast_GF_fam
IPR008996	IL1/FGF

PROSITE

PROSITE ID	PROSITE Term
PS00247	HBGF_FGF

Pfam

Pfam ID	Pfam Term
PF00167	FGF

Gene: FGF2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

There is no orthologous record for this gene !

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction